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Abstract: Schizophrenia is a highly heritable, chronic, severe, disabling neurodevelopmental brain
disorder with a heterogeneous genetic and neurobiological background, which is still poorly
understood. To allow better diagnostic procedures and therapeutic strategies in schizophrenia
patients, use of easy accessible biomarkers is suggested. The most frequently used biomarkers in
schizophrenia are those associated with the neuroimmune and neuroendocrine system, metabolism,
different neurotransmitter systems and neurotrophic factors. However, there are still no validated and
reliable biomarkers in clinical use for schizophrenia. This review will address potential biomarkers
in schizophrenia. It will discuss biomarkers in schizophrenia and propose the use of specific
blood-based panels that will include a set of markers associated with immune processes, metabolic
disorders, and neuroendocrine/neurotrophin/neurotransmitter alterations. The combination of
different markers, or complex multi-marker panels, might help in the discrimination of patients with
different underlying pathologies and in the better classification of the more homogenous groups.
Therefore, the development of the diagnostic, prognostic and theranostic biomarkers is an urgent and
an unmet need in psychiatry, with the aim of improving diagnosis, therapy monitoring, prediction of
treatment outcome and focus on the personal medicine approach in order to improve the quality of
life in patients with schizophrenia and decrease health costs worldwide.
Keywords: schizophrenia; biomarkers; diagnostic; prognostic and theranostic biomarkers; inflammatory;
stress-related; metabolic; neurotrophic and neurotransmitter biomarkers
1. Vulnerability and Resilience in Mental Disorders
There are numerous environmental and biological factors that interact with genetic factors and
contribute to vulnerability or resilience with respect to the development of mental disorders [1].
Most psychiatric disorders, including schizophrenia, develop in vulnerable subjects who failed
to cope with stress and do not achieve positive outcomes when faced with adversities and
stressors [2]. Resilience is modulated by diverse systems (neurotransmitters, neurotrophic factors,
hypothalamic–pituitary–adrenal (HPA) axis, immune system, autonomic nervous system, oxidative
stress and metabolic markers), working together to recover from various stressors and stressful
experiences and to achieve a positive adaptation after exposure to stressors that are presenting
as threats to homeostasis [3,4]. Resilience may help understanding the heterogeneous therapeutic
outcomes in schizophrenia [4]. One of the major systems involved in the regulation of the stress is
the HPA axis, which shows enhanced activity (i.e., increased release of corticotrophin releasing
factor (CRH), adrenocorticotrophic hormone (ACTH) and cortisol) as a response to stress [5,6].
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The HPA axis is self-regulated, with a negative feedback mechanism which inhibits HPA axis activity;
and after the system responses to stress or challenge, the HPA axis returns to its “normal” activity,
i.e., homeostasis [5,6].
2. Schizophrenia
Schizophrenia is highly heritable, chronic, severe, disabling neurodevelopmental brain disease
with heterogeneous genetic and neurobiological background. Symptoms of schizophrenia include
positive, negative, cognitive and mood symptoms. Positive symptoms consist of psychotic symptoms,
such as hallucinations, delusions, and disorganized speech and behavior. Negative symptoms include
reduced emotions, poverty of speech, and loss of interests and drive, while cognitive symptoms
comprise of deficits in working memory, attention and in executive functions, such as the ability to
organize and abstract. Mood symptoms consist of depressive, cheerful or sad moods. Schizophrenia
is a complex, multifactorial and polygenic mental disorder, estimated to affect 1% of population
worldwide [1,2,7]. Stress, which modifies the HPA function, has been strongly implicated in the
etiology of schizophrenia [8]. The neural-diathesis stress model of schizophrenia hypothesizes
that schizophrenia develops as a consequence of the HPA axis dysregulation, and that different
neurotransmitters and neuroimmune factors, neuroanatomical structures, pathways and connectivity,
and genetic, epigenetic, neurodevelopmental and environmental factors modulate the main stress
system (i.e., HPA axis activity) in vulnerable subjects exposed to stress [9–11].
The development of schizophrenia is mediated by numerous risk factors [2]: prenatal and perinatal
complications, paternal older age, male gender, living in the urban environment, migration status,
drug abuse (especially cannabis, amphetamine, methamphetamine and cocaine), and exposure to
stressors (physical abuse, sexual abuse, maltreatment and bullying). The etiology of schizophrenia
is far from clear, but family, twin and adoption studies all point to the major role of genetic factors,
among other contributing factors, in its etiology [1]. Genetic factors might be associated with
vulnerability to the disorder (i.e., they represent risk factors) in the presence of negative environmental
influences (gene x environment interaction), and are proposed to be called plasticity variants,
since they moderate susceptibility to both negative as well as positive environmental influences [1].
However, like in other complex mental disorders, it is assumed that development of schizophrenia
is associated with complex interactions between various genetic risk factors, environmental factors,
and exposure to early traumatic experiences, which all together modulate/influence the long-lasting
neurodevelopmental changes in the neural circuits and neural pathways of the central nervous
system (CNS) and alter homeostasis. When these factors overcome resilient defense mechanisms,
schizophrenia will develop in vulnerable subjects. Therefore, genetic predisposition in accord with
negative environmental stimuli will trigger development of schizophrenia; while on the other hand,
without adverse environmental stimuli, genetic predisposition alone will not be responsible for
development of the disease [1].
3. Biomarkers
Due to diverse clinical phenotypes, symptoms and presentation, and heterogeneity of the
overlapping symptoms and functional deficits in schizophrenia [2,12], its underlying biological
background is poorly understood. Therefore, studies are focused on investigations of smaller,
more subtle, stable characteristics of the disease such as phenotypes, endophenotypes or intermediate
traits, associated with schizophrenia. To allow better diagnostic procedures, therapeutic strategies
and prediction of therapies [13], the use biomarkers that can be measured or determined from the
easily available body fluids such as plasma/serum, urine or cerebrospinal fluid (CSF) is suggested
(Figure 1). Biomarkers have three general functions: to improve diagnostic procedure as diagnostic
biomarkers, to predict development of the disease as prognostic biomarkers (predisposition screening),
and to be used in therapy monitoring as potential predictors of good or poor therapeutic response
as theranostic biomarkers [13,14]. Biomarkers should be used in complex psychiatric disorders such
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as schizophrenia, since their use could facilitate diagnosis, prognosis (risk), prediction of disease,
identification of specific symptoms, or pathological behaviors such as suicidal/aggressive/violent
behavior, treatment response, and development of adverse events [7,13,15–17].
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treatment response) is strongly recommended [13,16–18]. The term “theranostics” is defined as an 
answer to the unmet needs in medicine and in psychiatry to achieve personalized medicine 
approach in treatment; to improve diagnoses and to combine diagnostic processes with the best 
possible therapeutic strategies [18]. 
Biomarkers of schizophrenia may be divided into peripheral and central biomarkers. However, 
since schizophrenia is a disease of systemic nature, some biomarkers (i.e., analytes from the post 
mortem brains of patients with schizophrenia) are related to changes found in the blood, suggesting 
that brain/CNS and periphery are interconnected and therefore blood-based biomarkers are useful 
tools to reveal some processes in the brain [19]. These findings were recently confirmed and 
reviewed, since alterations in gene expression and epigenetic changes, together with alterations in 
proteomic and metabolic markers are detected in the CNS as well as in periphery [17]. This was 
explained by the reciprocal interactions that exist between the brain and the periphery, modulated 
by the neurotransmitters, hormones and cytokines, which affect gene expression of the peripheral 
indicators. On the other hand, the same molecules (hormones, neurotransmitters, or cytokines) 
might modulate central i.e., brain functions [17]. Biomarkers might be divided into those associated 
with the neuroimmune system (inflammatory biomarkers), neuroendocrine system (neuroendocrine 
related biomarkers), metabolism (metabolic biomarkers), neurotrophic factors (neurotrophic 
biomarkers), and neurotransmitters (neurotransmitter biomarkers), shown in Figure 2 [17]. 
Figure 1. Biomarkers that can be measured or determined from the post-mortem brain or using
in vivo neuroimaging studies, as well as from peripheral cells and easily available body fluids such as
plasma/serum, urine or cerebrospinal fluid (CSF).
To facilitate deeper understanding of the molecular, cellular and systems alterations in
schizophrenia, the use of diagnostic, prognostic but also theranostic biomarkers (i.e., novel tests
or indicators or biomarkers used to identify the individual patient who will benefit from the most
appropriate, efficacious treatment, given in the optimal dose, without toxic side effects and predict
treatment response) is strongly recommended [13,16–18]. The term “theranostics” is defined as
an answer to the unmet needs in medicine and in psychiatry to achieve personalized medicine
approach in treatment; to improve diagnoses and combine diagnostic processe with the best
possible therapeutic strategies [18].
Biomarkers of schizophrenia may be divided into peripheral and central biomarkers. However,
since schizophrenia is a disease of systemic nature, some biomarkers (i.e., analytes from the post
mortem brains of patients with schizophrenia) are related to changes found in the blood, suggesting
that brain/CNS and periphery are interconnected and therefore blood-based biomarkers are useful
tools to reveal some processes in the brain [19]. These findings were recently confirmed and
reviewed, since alterations in gene expression and epigenetic changes, together with alterations
in proteomic and metabolic markers are detected in the CNS as well as i periphery [17]. This was
explained by the r ciprocal interactio s that exist betwe n the brain an the periph ry, modulated
by the neurotransmitters, hormones and cytokines, which affect gene expressio of the pe ipheral
indicators. On the other hand, the same molecules (hormones, neurotransmitters, or cytokines) might
modulate central i.e., brain functions [17]. Biomarkers might be divided into those associated with the
neuroimmune system (inflammatory biomarkers), neuroendocrine system (neuroendocrine related
biomarkers), metabolism (metabolic biomarkers), neurotrophic factors (neurotrophic biomarkers),
and neurotransmitters (neurotransmitter biomarkers), shown in Figure 2 [17].
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In addition, there are also data showing an association of different perinatal inflammatory cytokines 
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connection between increased risk of schizophrenia and severe infection or autoimmune disease in 
anamnesis [24]. Besides, several genome-wide association studies (GWAS) emphasize a possible 
involvement of the major histocompatibility complex (MHC) locus and other immune regulatory 
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CRP, as an acute-phase marker of inflammation, is found in higher concentrations in patients 
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smoking. Perhaps this could be one of the explanations for inconsistencies between studies reporting 
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between CRP levels and schizophrenia [31]. CRP levels were determined in patients with chronic 
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[32]. An increase of serum CRP concentration after 8 weeks of olanzapine treatment was reported [32]. 
Other potential markers of schizophrenia are different types of cytokines, proteins that 
modulate inflammatory processes and have an important role in development of CNS. A 
meta-analysis included 14 studies dealing with cytokine concentrations in serum of the first episode 
schizophrenia patients and reported increased concentration of interleukin IL-1β, IL-6, IL-12, tumor 
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IL-2-receptor (sIL-2R) [33]. The same study suggested IL-1β, IL-6 and TGF-β as schizophrenia state 
markers, since they were elevated in both the first episode and the relapse of the disease, but these 
markers were decreased after antipsychotic treatment [33]. On the other hand, IL-12, IFN-γ, TNF-α 
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inhibitor expressed by macrophages, and IL-17 were even proposed to be a differentiating factor 
between pre-onset schizophrenia and bipolar disorder [35]. Besides, tumor growth factor (TGF)-α, 
CD5L, cluster of differentiation 40 (CD40), macrophage-derived chemokine and TNF receptor like 2 
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3.1. Inflammation Biomarkers in Schizophrenia
Severe infectious illnesses are often accompanied by specific symptoms of schizophrenia, such as
psychotic symptoms, mood disturbance and cognitive dysfunction [20]. A significant amount of
evidence suggests that inflammation is a contributing factor to the pathophysiology of schizophrenia,
and in agreement, changes in immunological markers have been found in blood, such as C-reactive
protein (CRP) or different interleukins (IL) of patients with schizophrenia [21,22]. In addition,
there are also data showing an association of different perinatal inflammatory cytokines with the
development of schizophrenia later in life [23]. Some epidemiologic studies imply a connection
between increased risk of schizophrenia and severe infection or autoimmune disease in anamnesis [24].
Besides, several genome-wide association studies (GWAS) emphasize a possible involvement of the
major histocompatibility complex (MHC) locus and other immune regulatory regions in schizophrenia
susceptibility [25].
CRP, as an acute-phase marker of inflammation, is found in higher concentrations in patients with
schizophrenia than in healthy control subjects [26,27]. More specifically, higher CRP levels are shown
to be associated with the severity of schizophrenia symptoms evaluated by the Positive and Negative
Syndrome Scale (PANSS) [28,29]. Since elevated CRP levels are in correlation with an increased risk of
metabolic syndrome in schizophrenia [30], there is an unmet need for researchers to control their results
for possible confounding factors such as body mass index (BMI), gender or smoking. Perhaps this
could be one of the explanations for inconsistencies between studies reporting elevated serum CRP
levels in patients with schizophrenia and those reporting no association between CRP levels and
schizophrenia [31]. CRP levels were determined in patients with chronic schizophrenia treated with
different types of antipsychotics and switched to olanzapine treatment [32]. An increase of serum CRP
concentration after 8 weeks of olanzapine treatment was reported [32].
Other potential markers of schizophrenia are different types of cytokines, proteins that modulate
inflammatory processes and have an important role in development of CNS. A meta-analysis included
14 studies dealing with cytokine concentrations in serum of the first episode schizophrenia patients
and reported increased concentration of interleukin IL-1β, IL-6, IL-12, tumor necrosis factor (TNF)-α,
transforming growth factor (TGF)-β, interferon (IFN)-γ and soluble IL-2-receptor (sIL-2R) [33].
The same study suggested IL-1β, IL-6 and TGF-β as schizophrenia state markers, since they were
elevated in both the first episode and the relapse of the disease, but these markers were decreased after
antipsychotic treatment [33]. On the other hand, IL-12, IFN-γ, TNF-α and sIL-2R were presented as
potential trait markers that do not normalize after the treatment [33]. Some other interleukins, such as
IL-1RA, IL-10 and IL-15 [34], were also found to be increased in schizophrenia, while IL-6R, cluster of
differentiation 5-like protein (CD5L), also known as apoptosis inhibitor expressed by macrophages,
and IL-17 were even proposed to be a differentiating factor between pre-onset schizophrenia and
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bipolar disorder [35]. Besides, tumor growth factor (TGF)-α, CD5L, cluster of differentiation 40 (CD40),
macrophage-derived chemokine and TNF receptor like 2 protein showed potential as predicting
markers of schizophrenia relapse [36].
Interleukins and their role in the etiology of schizophrenia are investigated through the observed
association between infections during pregnancy and risk for schizophrenia among offspring.
Rather broad literature data, although inconsistent, indicate a higher risk of schizophrenia in people
whose mothers were infected during pregnancy with influenza [37], rubella [38], polio [39], measles [40],
herpes simplex virus-type 2 [41], or Toxoplasma gondii (toxoplasmosis) [42]. Since placenta acts as
impermeable barrier for most infections, it is assumed that negative outcomes of maternal infections
are caused by maternal and fetal responses to infection, which are primarily mediated by cytokines [43].
For example, there are studies reporting elevated levels of TNF-α and IL-8 in perinatal period of adult
patients with schizophrenia [44,45]. More precisely, fetal exposure to increases in maternal IL-8 was
found to be significantly associated with increased ventricular cerebrospinal fluid volume [46], a most
commonly found brain disturbance in schizophrenia [47].
Schizophrenia shares similarities with some autoimmune diseases. In patients with schizophrenia,
there are reports on increased levels of different auto-antibodies such as lupus anticoagulants,
rheumatoid factors and antibodies against cardiolipin, N-methyl-D-aspartate (NMDA) receptor,
DNA and dopamine receptor, with anti-NMDA receptor antibodies as the differentiating factor
between schizophrenia and bipolar disorder [48]. Additionally, typical schizophrenia symptoms,
cognitive deficits and acute psychosis could be found in autoimmune diseases, such as systemic
lupus erythematosus [49]. Studies of autoantibodies in schizophrenia will hopefully contribute to
understanding the neurobiological basis of disorder and findings of new treatment solutions.
Genetic studies estimate approximately 50% contribution of genetics to schizophrenia [50].
GWAS revealed a possible involvement of MHC region in genetic background of schizophrenia [51].
The MHC region consists of over 200 genes, including the TNF superfamily, human leukocyte antigen
genes and complement cascade genes, and has an extremely important role in the regulation of immune
system [52]. Further, GWAS covered five major psychiatric disorders (autism spectrum disorder,
attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia)
and reported that particular polymorphisms (for example rs2021722) within the MHC region are
specific only for schizophrenia [53]. Additionally, alternate expression rates of the class I major
histocompatibility complex genes in postmortem hippocampus samples of patients with schizophrenia
were reported [54].
There are indications about the more effective treatment of schizophrenia symptoms with
antipsychotics combined with nonsteroidal anti-inflammatory drugs (NSAIDs) [55] or aspirin
as adjuvant therapy [56]. A study on mouse model of schizophrenia reported an attenuated
amphetamine-induced behavioral impairment in mice treated with risperidone in combination with the
NSAID celecoxib [57]. Additionally, in patients with first-episode psychosis, strong inflammation partly
interfered with the effectiveness of antipsychotic drugs, with higher levels of IL-6 and IFN-γ associated
with worse response to antipsychotic treatment [58]. In patients with schizophrenia seropositive for
Toxoplasma gondii, treatment with antipsychotics with anti-toxoplasmic activity showed better results
than treatment with antipsychotics without anti-toxoplasmic activity [59]. Meta-analysis including
23 follow-up studies found an increase of sIL-2 and decrease of IL-1β levels and IFN-γ after the
treatment with antipsychotics, concluding that antipsychotic drugs show anti-inflammatory effects
in schizophrenia [60]. Similarly, IL-1β, IL-6 and TNFα levels in serum of drug-naïve patients with
first-episode psychosis were reduced after risperidone treatment [61].
Based on the current findings, the conclusion is that although predictive value of inflammatory
biomarkers is still not completely defined, they still show great potential. Besides, these new findings
represent a great contribution to some promising new therapeutic approaches such as biological
immunotherapy in schizophrenia.
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3.2. Neuroendocrine-Related Biomarkers in Schizophrenia
3.2.1. The HPA Axis-Related Biomarkers in Schizophrenia
The HPA axis is important in development of schizophrenia since the HPA axis and
sympatho-adrenal medullary system both modulate response to stress, which is one of the factors
associated with its etiology. Besides stress, inflammation also significantly affects the HPA axis.
Biomarkers in schizophrenia are related to hormones of the neuroendocrine systems, and also hormonal
systems regulating metabolic system [14]. The HPA axis abnormalities and dysfunction are well
recognized in schizophrenia, offering potential biomarkers, since patients with schizophrenia usually
have elevated basal cortisol levels compared to values in healthy subjects [62–68]. These findings,
showing either no effect or a small-to-medium increase in morning cortisol levels in patients
with schizophrenia compared to controls, were confirmed in the recent meta-analyses [66,69].
These controversial results might be explained by the presence of various symptoms or different phases
of schizophrenia [70]. Besides basal levels, patients with schizophrenia usually show altered response
to challenge tests such as dexamethasone suppression test (DST) [62,63,65], CRH test [71], or DST/CRH
test [72]. Namely, these tests assess the negative feedback of the HPA axis after administration of
a challenge, and cortisol escape from suppression after DST is frequently seen in these patients [63,65].
DST non-suppression ranges from 0 to 81% [70]. In addition, HPA abnormalities are documented also
by the findings showing glucocorticoid receptor downregulation associated with altered and reduced
HPA axis system negative feedback mechanism, and increased cortisol secretion frequently related to
reduced hippocampal volume in schizophrenia [10,11].
However, these data are not in harmony, and the results from the studies show both HPA
hyper- and hypofunction in schizophrenia [70]. Patients with schizophrenia usually show diminished
cortisol awakening response (CAR), i.e., cortisol concentration immediately after awakening [64].
In addition to morning alterations, diurnal rhythm of cortisol secretion is altered in the afternoon and
evening in subjects with schizophrenia [73]. However, contradictory results can also be found [3,66,74].
Some recent reviews and meta-analyses were published to solve these contradictions: a meta-analysis
of the 44 studies (n = 2613) showed only a moderate increase in morning cortisol levels in patients with
schizophrenia compared to controls [66]. In a systemic review, in drug-naïve first-episode patients,
elevated cortisol secretion was detected [70]. In patients receiving antipsychotic medication, atypical
antipsychotic treatment (i.e., olanzapine, quetiapine and clozapine) usually decreases ACTH and
cortisol levels [70]. We have previously reported that the typical antipsychotic fluphenazine increases,
while the atypical antipsychotic olanzapine decreases, cortisol levels in patients with schizophrenia [75].
Therefore, a meta-analysis including a large group of medicated patients with schizophrenia (n = 1328)
concluded that cortisol levels did not differ from the values in control subjects, while in medicated
patients, most frequently treated with typical antipsychotics, cortisol is slightly increased compared to
values in healthy subjects [66]. These results suggest that careful consideration of present medication
use, type and doses is needed in the studies of the HPA axis biomarkers in schizophrenia. To exclude
these confounding factors, first-episode patients or drug-naïve patients should be used. However,
due to the complicated clinical picture of schizophrenia, biomarkers should be used also in patients
with a chronic course of schizophrenia. Therefore, abnormal response of the HPA axis in schizophrenia
is present, but cortisol is affected by numerous factors, such as body fluid (saliva or blood), time of
sampling, stage of the illness, various symptoms, antipsychotic medication and stress induced by
psychological and other environmental stressors [66,70]. Besides these factors, cortisol is under the
influence of development and age [11]. Therefore, components of the HPA axis such as moderately
increased cortisol, non-suppression to DST, altered diurnal rhythm of cortisol, and blunted or altered
cortisol response to physiological stressors might be used as neuroendocrine diagnostic biomarkers of
patients with schizophrenia, but should be compared to either drug-naïve patients or patients with
a first episode of psychosis [70].
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Genetic studies in neuroendocrine biomarkers of schizophrenia target most frequently two
genes, and their single nucleotide polymorphisms (SNPs): a gene for FK506 binding protein-5
(FKBP5), encoding the protein FKBP51, and a gene for corticotrophin-releasing hormone receptor 1
(CRHR1), encoding the CRH type 1 receptors. FKBP5 is a protein (i.e., a co-chaperone) important
in the stress response, and its genetic variants are involved in stress response since they affect
glucocorticoid receptor (GR) function and GR complex and therefore modulate negative feedback.
A risk variant of the FKBP5 associated with higher FKBP5 induction may provoke prolonged cortisol
release after stress, since it impairs the binding of cortisol to GR complex and inhibits its affinity
to GR, decreases translocation, and impairs the negative feedback mechanism, leading to different
psychopathologies and personality traits, altered responses to stress, disrupted homeostasis, epigenetic
changes (FKBP5 SNP rs1360780), and changes in the neural pathways, brain function and synaptic
plasticity [1,76]. The rs1360780 risk allele of the FKBP5 influences different regions of the brain
associated with response to fear, threat and stress (amygdala and hippocampus), and in combination
with exposure to early traumatic experience affects the amygdala and other brain regions connected to
reactivity, emotional memory, and emotion processing. All these changes are associated with impaired
reactions to threat and activated HPA axis. This particular gene x environment interaction induces
altered responses to fear and stress associated with different psychopathological phenotypes [1,76].
FKBP5 overexpression was found in different regions of the postmortem brains, which are associated
with Alzheimer’s disease and schizophrenia [76]. Different SNPs of the FKBP5 and their risk genotypes
(rs3800373, rs9296158, rs1360780, and rs9470080) interacted with early traumatic experiences and were
associated with aggressive and violent behaviors [77]. FKBP5 SNPs (rs9296158, rs1360780, rs1043805,
and rs4713916) were also found to interact with childhood trauma to predispose to development of
psychotic symptoms [78]. Besides these aberrant behaviors frequent in psychiatric disorders, FKBP5
was reported to be increased in human adipose tissue after dexamethasone, implicating its role in
metabolic disorders such as insulin resistance [79]. These results all suggest that FKBP5 disinhibition
might be used to characterize endophenotypes sensitive to stress, associated with various stress-related
disorders, and therefore the blockade of the FKBP5 might be used in the treatment of different
phenotypes induced by stress [76].
Another genetic component of the HPA axis that is frequently investigated is a gene for
CRHR1. These CRHR1 regulate HPA axis activity and its negative feedback, and therefore its genetic
variants modulate CRH transmission, and under other environmental factors such as childhood
trauma may induce changes in CRHR1 signaling and HPA axis disruption, and altered stress
response [1]. Gene coding for the CRH binding protein (CRHBP) was investigated in schizophrenia.
The heterozygous genotype of the CRHB (rs1875999) was significantly associated with suicidal
attempts, while the rare variant of BclI polymorphism in the glucocorticoid receptor gene (NC3R1)
11 was associated with protection from suicidal attempt in schizophrenic patients [80]. In addition,
the interaction between the two genes related to HPA axis, CRHR1 and CRHBP was detected in patients
who attempted suicide and with severity of suicidal behavior in schizophrenia [80]. The association
between CRHR1 and CRHBP genes with severity of suicidal behavior was found in patients with
schizophrenia [80]. All these genetic studies point to the importance of the gene x environment
interactions, and suggest that genes coding for proteins important in the regulation of the HPA axis
and stress response may contribute to long-lasting changes in the HPA axis function, and may alter
and disrupt negative feedback mechanism, homeostasis and emotion regulation, leading to different
mental disorders and altered behaviors [1].
3.2.2. Metabolic Biomarkers
Somatic disorders such as metabolic disorders as well as metabolic syndrome, type 2 diabetes,
insulin resistance and different cardiovascular diseases are frequent in schizophrenia [67,81].
Patients with schizophrenia have increased risk of having higher than normal body mass index
(BMI), being smokers, having increased glucose levels, and developing diabetes, hypertension and
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dyslipidemia, all risk factors for cardiovascular disease, compared to healthy people [82]. Expression
of various hormones was found to differ significantly between patients with schizophrenia and control
subjects: insulin, prolactin, pancreatic polypeptide, progesterone and chromogranin A (a protein of
the granin family composed of 439 amino acids that is located in the large dense-core vesicles of
the neuroendocrine cells) were increased, while growth hormone was decreased in patients with
schizophrenia compared to control subjects [67]. These results might explain how chronically elevated
insulin levels affect brain function and contribute to neuroinflammation, altered phosphorylation
and promote deposition of amyloid plaques, leading to changes characteristic of dementia [14].
Neuroendocrine biomarkers, such as cortisol, insulin, leptin, pro-opiomelanocortin, prolactin and
growth hormone were similarly altered in the brain and in the blood in patients with schizophrenia [19].
Other neuroendocrine biomarkers altered in schizophrenia are gonadal hormones estradiol and
testosterone, suggesting gender differences in schizophrenia [14], as well as hormones of the
thyroid gland such as decreased thyroxine, tri-iodothyronine, and thyroid-stimulating hormone [83],
suggesting that these biomarkers might represent peripheral plasma markers of oxidative stress and
thyroid dysfunction in schizophrenia.
There are controversial findings of the levels of the neurosteroids dehydroepiandrosterone (DHEA)
and DHEA sulphate (DHEAS), collectively known as DHEA(S), in schizophrenia [84]. They have
neuroprotective and neuromodulatory effects, and were reported to be increased, decreased or similar
in schizophrenic patients compared to healthy control subjects [84]. In addition, there are also findings
showing the augmentation strategies using DHEA(S) in the treatment of schizophrenia: in studies
performed on a small number of patients, addition of DHEA(S) as the augmentation strategy improved
somatic health, decreased insulin resistance and inflammatory markers and had positive effects on the
quality of life or physical disability [84].
These results confirm that some indicators of metabolic syndrome or insulin resistance, or the
hypothalamic–pituitary–adrenal–gonadal axis are present in patients with schizophrenia, and that
these neuroendocrine and/or metabolic biomarkers might be used to discriminate between patients
with or without the risk for metabolic disorder, improve the understanding of the pathophysiological
processes associated with schizophrenia, advance the development of treatments focused on these
endocrine and metabolic disorders and consequently help in personalized medicine strategies [14,67].
3.3. Neurotrophins as Candidate Biomarkers in Schizophrenia
3.3.1. Brain-Derived Neurotrophic Factor
Neurotrophins play a significant role during the development of the nervous system by promoting
neuronal growth and differentiation, but they are also very important in the adult brain since they
modulate neuronal plasticity and function. Nerve growth factor (NGF), brain-derived neurotrophic
factor (BDNF), neurotrophin (NT)-3 and NT-4/5 are the members of neurotrophin family which are
located in the mammalian brain. All of these neurotrophins are synthetized as pro-neurotrophin
precursors which are then proteolytically cleaved to yield mature proteins [85]. Binding to
an appropriate tyrosine kinase receptor (Trk) or pan neurotrophin receptor (p75NTR) activates
different signaling pathways leading to specific and diverse biological effects of neurotrophins [86].
Lately, neurotrophins and their precursors have aroused great interest as the possible players in
the pathophysiology of several psychiatric disorders, including schizophrenia. According to the
neurodevelopmental hypothesis, schizophrenia is considered to be the result of pathologic processes
that began during pre- and post-natal development of the CNS [87]. Since BDNF has an important role
in the processes of CNS development and maintenance, it is considered to be one of the main players
in light of the neurodevelopmental hypothesis.
Studies have shown significantly reduced expression of BDNF gene, gene coding for TrkB
receptor, and significantly decreased BDNF protein concentration in the hippocampus of patients with
schizophrenia [88,89]. However, a study by Durany and colleagues further pointed out an increased
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BDNF concentration in cortex of individuals with schizophrenia [89]. Meanwhile, there is also evidence
of lower BDNF levels in prefrontal cortex and in CSF of subjects diagnosed with schizophrenia [90].
In the last decade, many research strategies have focused on the peripheral BDNF as a potential
biomarker in psychiatry. The sources of the peripheral BDNF are platelets and immune and
vascular endothelial cells [91,92], but there are also indications that BDNF is able to cross the
blood–brain barrier [93]. Studies of BDNF as a peripheral biomarker in psychiatric disorders, including
schizophrenia [94], are supported by a strong positive correlation between peripheral BDNF levels
and BDNF levels in the CNS [95,96]. Low serum BDNF protein levels were determined in drug-naïve
patients with schizophrenia [97–100], but also in schizophrenic patients who were treated with
different antipsychotics [101–105]. These results were confirmed by a meta-analysis, which included
16 individual studies [106]. A significant correlation between serum BDNF levels and clozapine daily
dose was found, suggesting also that the treatment with clozapine can lead to cognitive enhancement
in patients with schizophrenia [107]. Another study, which drew attention to the existence of three
different isoforms of BDNF in the serum, (i.e., precursor, mature and truncated forms of BDNF),
suggested that individuals with schizophrenia have lower levels of truncated isoform, compared
to other forms of BDNF [108]. The biological role of the truncated isoform of BDNF has not yet
been clarified. Animal studies demonstrated a significant effect of antipsychotic treatment on BDNF
brain levels. Treatment with haloperidol decreased BDNF messenger RNA (mRNA) and protein
levels in different brain areas, including hippocampus and prefrontal cortex [109–111], and a similar
effect was observed for risperidone administration [109]. In addition, a switch from haloperidol,
which negatively affects the expression of BDNF, to olanzapine treatment, restored BDNF levels to
normal values [112]. Findings by Chlan-Fourney and colleagues demonstrated that hippocampal
BDNF mRNA expression is affected by chronic, but not acute treatment with antipsychotics [113].
The observed effect was most likely a result of long-term changes in gene regulation, rather than
blockade of the serotonergic receptors type 2 (5-HTR2) and dopaminergic receptors type 2 (DRD2).
Even though existing studies have failed to irrefutably prove the effect of treatment with antipsychotics
on peripheral BDNF concentration and mRNA expression, there is a need for additional investigations,
which will help to further clarify the role of neurotrophins in the response to treatment with different
atypical antipsychotics.
The association studies between genetic polymorphisms of BDNF and schizophrenia resulted in
contradictory findings. Literature search usually yields results concerning two of the most common
SNPs of the BDNF gene, Val66Met (rs6265) and C270T (rs56164415). Polymorphism Val66Met is
functional since it affects the BDNF mRNA intracellular trafficking and the activity-dependent
secretion of BDNF protein by disturbing the interaction of BDNF with transport molecules like
sortilin [114,115]. The C270T polymorphism is assumed to modulate the BDNF gene expression
and post-transcriptional regulation of this expression, due to its position in the 5′ untranslated
region and the assumptions that it is located within CpG islands [116]. Some studies have
shown that the BDNF Met allele or the Met/Met genotype is associated with the increased risk
of developing schizophrenia [117,118]. However, it was also reported that the BDNF Val allele
could be related to lower hippocampal volume [119] and be one of the genetic risk factors for
schizophrenia [120,121]. Most of the studies linking BDNF Val66Met to schizophrenia found no
association between this polymorphism and development of schizophrenia [122–126]. Even though
a meta-analysis conducted by Zintzaras found no evidence for the association between BDNF Val66Met
polymorphism and schizophrenia, it suggested a possible association between schizophrenia and
the other SNP, BDNF C270T polymorphism [126]. This association was confirmed in the East Asian
population by another meta-analysis based on 13 case-control association studies [127], suggesting
that the T allele may contribute to predisposition to schizophrenia. Some other authors also observed
a higher frequency of the T allele carriers and C/T heterozygotes in subjects with schizophrenia,
compared to healthy individuals [128,129]. However, there are studies that did not confirm these
results [123,124,130]. Genetic variants of BDNF were also reported to be significantly associated
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with response to treatment with antipsychotics. Few studies reported association between BDNF
Val66Met polymorphism and treatment response in schizophrenic patients, indicating a higher
frequency of the Val/Val homozygotes in clozapine treatment responders [131,132], and olanzapine
treatment responders [133], compared to non-responders. However, there are studies that failed to
confirm the above mentioned associations between the BDNF Val66Met polymorphism and clozapine
treatment response [134,135]. Study by Zai and colleagues also suggested an over-representation
of the rs11030104 T/T genotype and the T allele in responders compared to non-responders,
and an association between the marker rs1519480 and antipsychotic-induced weight gain [132].
Another genetic BDNF marker, dinucleotide microsatellite repeat polymorphism (GT)n, was associated
with treatment response and chlorpromazine-induced extrapyramidal reverse effects in Chinese
patients with schizophrenia [136]. Other studies have linked antipsychotic-induced weight gain
with BDNF genetic variants, including BDNF Val66Met polymorphism [137], rs11030101 [138],
and rs1519480 [132]. A systematic review and a meta-analysis by Cargnin and colleagues, which
included nine different studies, found no evidence that would irrefutably support the involvement of
BDNF gene variants in the antipsychotic drug response [139]. However, these authors suggested that
future studies should focus on haplotype combinations, which include BDNF Val66Met polymorphism
with other BDNF SNPs.
Different epigenetic mechanisms are responsible for activity-dependent regulation of BDNF gene
expression [140,141], implicating the possible role of the regulation of BDNF expression in several
psychiatric disorders including schizophrenia [142–144]. There are only a few studies that investigated
the promoter methylation frequency in patients with schizophrenia. Mill and colleagues found no
difference in DNA methylation profiles between patients with schizophrenia and bipolar disorder,
compared to healthy controls [145]. A study by Igekame and colleagues revealed the hypermethylation
of one CpG site in the BDNF promoter I and no difference in the BDNF promoter IV methylation
frequency between schizophrenic patients and healthy individuals [146]. However, the results from
the other study suggested a difference in the promotor IV methylation frequency and BDNF gene
expression between patients diagnosed with schizophrenia and control subjects [147]. Yet the question
remains as to whether the alterations in methylation status of specific genes are directly associated
with the pathophysiology of schizophrenia, or are a consequence, at least in part, of an antipsychotic
treatment. Global DNA hypomethylation was reported in the leukocytes of patients diagnosed with
schizophrenia [148], which could be related to the chronic treatment with different antipsychotics
demonstrating DNA-demethylation activity [149].
3.3.2. Other Neurotrophins
There are only few studies that have addressed the role of other neurotrophins in pathophysiology
of schizophrenia. Decreased NT-3 levels in the cortex of schizophrenia patients compared to
non-psychotic individuals were detected [89]. Different gene association studies suggested an
association between dinucleotide repeat polymorphism in the promoter region of gene coding for
NT-3 and schizophrenia [150,151], but these results were not confirmed [152]. However, the carriers of
A3/147-bp allele in a dinucleotide repeat polymorphism were reported to have earlier age of onset and
more serious extrapyramidal symptoms [153]. Another NT-3 polymorphism, Gly63Glu, which results
in an amino acid substitution of glycine by glutamic acid at position 63, has also been associated with
schizophrenia, earlier age of onset and the duration of illness [154].
A few recent studies demonstrated reduced NGF blood levels in the first-episode schizophrenia
patients compared to healthy individuals [155,156]. Decrease in NGF and NGF receptor (NGFR) blood
levels was confirmed in drug-naïve schizophrenia patients and patients treated with haloperidol [157].
In addition, an association between different NGF (rs6330, rs4839435) and NGFR (rrs11466155,
rs2072446, rs734194) polymorphisms and schizophrenia were also found [157].
There is convincing evidence of an association between BDNF and schizophrenia. Even though
changes in the mRNA expression and protein concentration of BDNF and other neurotrophins in the
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brain and at the periphery are not specific only for schizophrenia patients, further studies are needed
to determine if these systemic alterations are the cause or consequence of the neurodevelopmental
changes in schizophrenia.
3.4. Neurotransmitter Biomarkers
3.4.1. Dopaminergic System
Various findings demonstrated the hyperfunction of dopaminergic system in the mesolimbic system
of patients with schizophrenia creating the “dopamine (DA) hypothesis of schizophrenia” [158–162].
This classical DA hypothesis of schizophrenia was mostly concerned with the hyperactivity of DA
signaling in subcortical regions such as striatum [162–166], and with significant role of DRD2 in
the development of positive symptoms [167–170]. This dopaminergic hypothesis of schizophrenia
has been also supported by the correlation between efficacy of antipsychotic drugs in treating
schizophrenia and their potency to antagonize the binding of DA to DRD2 [171–173], as well as
by the ability of dopaminergic agents, such as psychostimulant amphetamine, to induce excessive
release of striatal DA and stimulate schizophrenia-like psychosis [174–176]. However, enduring
negative and cognitive symptoms of schizophrenia, resistant to DRD2 antagonist treatment, suggested
that they might be due to a deficit in the prefrontal cortex (PFC) DA transmission at DRD1 [177–180].
According to this hypothesis of cortical/subcortical imbalance in schizophrenia, hypoactive DA
neurotransmission in PFC, resulting in hypostimulation of DRD1, and negative and cognitive
symptoms, leads to disinhibition of subcortical mesolimbic DA activity, resulting in hyperstimulation
of DRD2 and positive symptoms of schizophrenia [159,181–183]. Therefore, the optimal schizophrenia
treatment should increase DA activity in the mesocortical regions and decrease mesolimbic DA
activity [184]. These findings also stimulated further research investigating the risk genes involved in
the pathophysiology of schizophrenia [185]. These genetic studies also included the polymorphisms
in the genes coding for various DA receptors and their association with schizophrenia [186–189],
as well as with antipsychotic treatment response [190–193], however with contradictory results.
Various markers of dopaminergic function have been also investigated in the blood of subjects with
schizophrenia [194], in order to find peripheral biomarkers. For instance, DA uptake by platelets was
shown to correlate with delusional state in subjects with schizophrenia [195]. Tyrosine hydroxylase
(TH), the enzyme involved in the synthesis of DA, has been reported to be increased in lymphocytes of
schizophrenia patients [196]. Although elevated lymphocyte mRNA levels of DA transporter (DAT)
were demonstrated in patients with schizophrenia [197], reduced density of the lymphocyte DAT
proteins was reported in psychosis [198]. The plasma or CSF levels of homovanillic acid (HVA),
the principal DA metabolite, were found to be elevated in schizophrenia [199–202], and to predict
response to antipsychotics drugs [203–205]. Some authors reported the up-regulation of DRD2 mRNA
expression and DRD2 binding in lymphocytes from schizophrenia patients [206,207], although other
studies have not confirmed these findings [197,208]. In addition, DRD2 mRNA levels in lymphocytes
are suggested to correlate with positive symptoms of schizophrenia [197], whereas lymphocyte DRD2
binding was reduced after treatment with antipsychotic drug loxapine [209]. The results regarding
DRD3 were also conflicting, demonstrating increased [208,210,211], as well as decreased [212] levels of
lymphocyte DRD3 mRNA in schizophrenia. DRD4 mRNA in lymphocytes was found to be lower [208],
or un-changed [197] in patients with schizophrenia compared to control subjects. The changes in
lymphocyte DRD3 and DRD5 mRNA seem to be associated with schizophrenia symptom severity [211],
with increased levels observed following antipsychotic treatment [211,212]. Moreover, some studies
demonstrated the increased binding of DA antagonists in lymphocytes of subjects with schizophrenia
in comparison to control group [206,213], as well as in responders to antipsychotic treatment as
compared with treatment-resistant schizophrenia patients [214].
Genes associated with schizophrenia and antipsychotic drug response include the catechol-O-
methyl transferase (COMT) gene, coding for an enzyme involved in the catabolism and regulation of
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DA levels in the PFC [215,216]. Various studies linked schizophrenia with a region on chromosome
22q11.2, where the COMT gene has been located [217,218]. Many association studies investigated
Val158/108Met (rs4680) functional polymorphism in the COMT gene. The Val/Val genotype of this
polymorphism, which results in the higher COMT activity compared to Met/Met genotype, may lead
to a decreased DA neurotransmission in PFC [219,220], characteristic for schizophrenia [221]. However,
the studies yielded inconsistent results, associating both the high activity “Val”, and low activity
“Met” alleles with schizophrenia [215,222–226], or failing to detect any association [227,228]. The more
recent meta-analysis found only a weak association of this polymorphism with schizophrenia [229].
Inconsistent associations of Val158/108Met in subjects of Asian origin have been attributed to another
COMT gene polymorphism, Ala72Ser (rs6267) [230]. Other reports also demonstrated the association
of additional COMT polymorphisms and haplotypes with schizophrenia [231–234], as well as the
synergistic effects of COMT gene with genes involved in other neurotransmitter systems [235,236].
In addition, the hypomethylation of the COMT gene promoter, which leads to over-expression
of COMT, has been found in post-mortem brains [237], as well as in peripheral blood cells of
schizophrenia patients [148,238,239]. As COMT hyperactivity in schizophrenia might result in
decreased dopaminergic neurotransmission in the PFC, and consequently to the development of
negative and cognitive symptoms of schizophrenia [215], different COMT inhibitors have been
investigated for potential treatment [240–246]. It has been demonstrated that COMT inhibition
potentiates the increase in extracellular DA in PFC elicited by the antipsychotic drug clozapine [247].
Regarding antipsychotic response, the findings of the studies investigating the role of COMT
Val158/108Met polymorphism were also conflicting, showing that schizophrenia patients with
Met/Met genotype have poor [248], as well as good response to antipsychotic treatment [233,249–253].
However, some authors found no association of this polymorphism with the therapeutic response
to antipsychotic drugs [254–256]. In addition, higher daily antipsychotic doses seem to be needed in
schizophrenia patients, homozygous for the Met allele [257,258]. Other polymorphisms and haplotypes
in the COMT gene have been also associated with response to antipsychotic treatment [233,251,259].
3.4.2. Serotonergic System
The involvement of the serotonergic system in schizophrenia was suggested from the studies
demonstrating that lysergic acid diethylamide (LSD), structurally similar to serotonin (5-HT), produces
various schizophrenia-like symptoms [260], as well as from the ability of some atypical antipsychotics,
such as clozapine, to improve symptoms of schizophrenia by modulating the 5-HT concentration [261].
It has been suggested that dopaminergic hypofunction, observed in schizophrenia, might be due
to the up-regulation of ascending serotonergic pathways [262]. The disturbed interconnectivity
between serotonergic and dopaminergic [263], as well as between serotonergic, cholinergic and
gamma-amino-butyric acid (GABA)ergic systems in the cortex and hippocampus [264,265], might play
an important role in the complex pathophysiology of schizophrenia [266]. The decrease in the density
of the 5-HT transporter (5-HTT), increase in 5-HTR1A number and reduction of 5-HTR2 levels in
the brain have been most frequently reported evidence of the involvement of serotonergic system
in schizophrenia [260]. Various 5-HT receptors have been particularly associated with cognitive
impairment in schizophrenia [267]. Reports from post-mortem studies have shown reduction in the
5-HTT number [268,269]. Moreover, a recent meta-analysis reported increased 5-HTR1A binding in
PFC, but diminished or unchanged in the amygdala [270]. Since stimulation of 5-HTR1A was found to
promote the release of dopamine in PFC, it is possible that the effects of antipsychotic drugs such as
clozapine, ziprasidone and aripiprazole are partly achieved by their agonistic action via 5-HTR1A [271].
Increased hippocampal 5-HTR1B mRNA levels were also observed in subjects with schizophrenia [272].
In spite of the conflicting results obtained in vivo [273,274], reduced density of prefrontal 5-HTR2A
has been found in the post-mortem studies of schizophrenia [270]. Concerted 5-HTR1B up-regulation
and 5-HTR2A down-regulation could result in decreased GABAergic and increased glutamatergic
activity in the hippocampus of schizophrenia patients [272]. Although no changes in the number of
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5-HTR3 and 5-HTR4 were found in the brain of schizophrenia patients [275,276], the associations of
5-HTR3E and 5-HTR4 gene variants with schizophrenia have been reported [277,278]. Various studies
also supported the role of 5-HTR7 in the neurobiological basis in schizophrenia, including reduction in
the 5-HTR7 expression in the hippocampus and prefrontal cortex [279,280], the association of 5-HTR7
gene haplotype with development of schizophrenia [281], the affinity of some antipsychotic drugs for
5-HTR7 [279,282], and the up-regulation of 5-HTR7 following antipsychotic treatment [279]. Studies
measuring peripheral serotonergic biomarkers found contradictory results. Increased platelet 5-HT
concentration has been demonstrated in schizophrenia patients [283–285]. However, lower baseline
5-HT concentrations in plasma and platelets were observed in poor responders to antipsychotic drugs
in comparison to control subjects and increased significantly during treatment [286]. On the other
hand, Kaneda and colleagues reported lower platelet 5-HT in the subjects with schizophrenia receiving
antipsychotic treatment [287]. Potential association of genetic variations of 5-HT receptors and 5-HTT
with schizophrenia and therapeutic response to antipsychotics has been intensively investigated in
a large number of studies [288–290]. Genetic polymorphisms of 5-HTR2A and 5-HTR2C, at which
act many antipsychotic drugs, have been the main targets of pharmacogenetic analyses [192,291,292].
However, some studies found no associations between polymorphisms in genes encoding 5-HT
receptors and 5-HTT with antipsychotic treatment response [190,293]. Regarding the involvement of
serotonergic system in the development of side effects of antipsychotics, pharmacogenetic research has
focused primarily on weight gain [294–297], while relatively small number of studies has investigated
the extrapyramidal side effects [298]. Although some authors reported the associations between tardive
dyskinesia and 5-HTR2A and 5-HTR2C gene polymorphisms, the results are not uniform [299,300].
In addition to genetic research, some epigenetic studies have demonstrated DNA methylation changes
such as hypermethylation of HTR1A gene [301], and differential methylation of the HTR1E gene [238] in
peripheral blood cells of schizophrenia patients. Based on current findings, different authors suggested
agents modulating 5-HTR2C [302,303], 5-HTR3 [304], and 5-HTR6 [305], as potential schizophrenia
drug targets.
3.4.3. Norepinephrine System
A number of studies supported the norepinephrine hypothesis of schizophrenia [306], suggesting that
elevated norepinephrine signaling may be involved in the pathophysiology of schizophrenia [307–310].
Increased concentrations of 3-methoxy-4-hydroxyphenylglycol (MHPG), the metabolite of norepinephrine,
were demonstrated in plasma of subjects with schizophrenia [205], but not in CSF [311]. On the other
hand, decrease in plasma MHPG was observed during treatment to antipsychotic treatment [312,313].
However, antipsychotic drugs risperidone and clozapine have been shown to elevate plasma
norepinephrine levels, whereas risperidone produced a smaller effect [314]. Therapeutic approaches
using norepinephrine drugs, especially α-2A agonists, in combination with antipsychotics have been
proposed for treatment of cognitive impairments in schizophrenia [315].
3.4.4. Cholinergic System
The cholinergic system has been associated with schizophrenia in various reports [316], mainly
suggesting down-regulation of cholinergic activity [317]. Decreased mRNA levels for α-7 acetylcholine
receptors have been found in the post-mortem brain [318], as well as in lymphocytes of subjects with
schizophrenia [319]. Post-mortem studies demonstrated lower α-7 nicotinic receptor binding in the
hippocampus and thalamic nuclei [320,321], as well as reduced α-7 receptor protein expression in
the frontal cortex of subjects with schizophrenia [322]. Disturbed cholinergic function, particularly
involving nicotinic receptors, has been linked with higher smoking frequency among schizophrenia
patients in comparison to general population [323]. Some studies also suggested a nicotinic cholinergic
α-7 receptor as a promising target for therapy of cognitive deficits in schizophrenia [324,325].
An increasing body of evidence has also implicated muscarinic system as contributing to a number
of symptoms of schizophrenia, especially related to cognitive impairment [326]. Down-regulation
Int. J. Mol. Sci. 2017, 18, 733 14 of 38
of muscarinic receptors has been observed in large areas of the post-mortem brain of patients with
schizophrenia [327,328]. Allosteric modulation of the M1 muscarinic acetylcholine receptor has been
proposed as a potential target for therapeutic interventions in schizophrenia [329].
3.4.5. Glutamatergic System
Different schizophrenia susceptibility genes and various schizophrenia-related environmental
factors influence glutamatergic neurotransmission [330–334]. However, one of the main findings
supporting the glutamatergic hypothesis, based on the glutamate-dopamine dysbalance in
schizophrenia, is that phencyclidine and ketamine produce psychosis, with positive, negative and
cognitive symptoms, resembling those in subjects with schizophrenia [335–337]. Treatment with
these N-methyl-D-aspartate receptor (NMDAR) antagonists induce schizophrenia-like dopaminergic
dysregulation in human subjects [338], as well as in animal models [339]. Post-mortem studies
have shown variable changes in the expression of NMDAR in the brain of schizophrenia
patients [340–342]. On the other hand, some studies indicated greater sensitivity of NMDAR in
patients with schizophrenia [343]. The involvement of abnormal glutamate transmission in various
impaired neurophysiological measures, observed in schizophrenia, has been suggested by Javitt and
colleagues [344]. In agreement with the proposed role of glutamatergic system in the pathophysiology
of schizophrenia [173], many researchers investigated the peripheral levels or functions of various
amino acids that activate glutamate receptors and modulate glutamatergic neurotransmission [343].
In addition to reduced markers of glutamatergic neuronal integrity in the plasma and CSF of
schizophrenia patients [345], lower concentrations of glutamate [346], glycine [332,347], and D-serine
were observed [348]. However, some studies demonstrated increased concentrations of glutamate [349],
agmatine [350], glutamine [351], D-serine and glycine [352] in plasma or blood from subjects
with schizophrenia, in comparison to control subjects. Lower plasma D-serine and D-/L-serine
ratio were found in the treatment-resistant schizophrenia patients, whereas glycine levels and
glycine/L-serine ratio were increased following clozapine treatment [353]. In addition, D-serine
plasma levels were associated with improvements in positive [352], but not in cognitive symptoms of
schizophrenia [354]. Agonists acting via glycine-site of NMDAR induced improvements in negative
and cognitive symptoms, whereas D-serine and sarcosine, administered together with antipsychotics,
reduced positive symptoms in patients with schizophrenia [355–357]. In addition to NMDAR, the
potential glutamatergic drug targets for schizophrenia treatment include also metabotropic (mGluR2/3)
glutamate receptors [358–360].
3.4.6. GABAergic System
Various research evidence support abnormal GABAergic neurotransmission in schizophrenia [361–367].
One line of findings came from the post-mortem studies demonstrating a decrease in the density, as well
as specific abnormalities of GABAergic interneurons, in the hippocampus and PFC of schizophrenia
patients [362,366], regions important for the somatosensory information processing. The hypothesis of
dysfunctional GABAergic interneurons is supported by the observed hypermethylation in cortex and
basal ganglia of subjects with schizophrenia [368–373], resulting in a down-regulation of GABAergic
genes and GABAergic neuronal circuit dysregulation [369,374,375]. Such hypermethylation has been
observed also in peripheral blood lymphocytes from patients with schizophrenia [376]. One of such
hypermethylated genes is the gene coding for glutamic acid decarboxylase (GAD), the rate-limiting
enzyme in GABA biosynthesis, for which expression is found to be generally lower in post-mortem
brain of schizophrenia patients compared to controls [361,377–381]. In accordance with this hypothesis
of GABAergic hypofunction in schizophrenia, GABAA receptor agonists might have beneficial effects
when administered alone or in combination with antipsychotic drugs. Some of the other results
suggesting GABAergic neuropathology in schizophrenia include lower GABA levels in plasma
of subjects with schizophrenia [199], down-regulation of prefrontal GABAA receptor α5 subunit
mRNA [382], and the associations of different polymorphisms and haplotypes in the GABAA receptor
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β2 subunit gene (GABRB2) with schizophrenia [383]. Moreover, the density of the peripheral-type
benzodiazepine receptors in platelets is suggested as a possible predictor for aggressive behavior in
schizophrenia patients [384].
4. Conclusions
Schizophrenia is a complex disease associated with different alterations in the brain circuits
and molecular pathways, characterized with different signs and completely different symptoms [2].
This review described the potential of the use of specific markers associated with immune processes,
or with metabolic disorders or neuroendocrine/neurotrophin/neurotransmitter alterations that might
help in discrimination of patients with specific, different underlying pathology or treatment response.
Better classification or definition of the more homogenous groups will improve understanding of
the biological underpinning of schizophrenia, and consequently improve treatment strategies and
personal medicine approaches. This was recently confirmed in first episode psychosis patients, where
non-responders to treatment had significantly lower CAR and significantly higher IL-6 and IFN-γ
levels than responders to treatment [58]. These data suggested that blunted CAR in combination with
proinflammatory IL-6 and IFN-γ levels that were elevated in non-responders could be used as trait
markers, and as predictors of the poor treatment response [58]. The combination of selected cytokines
(sIL2—increased by antipsychotics, and IL-1β and IFN-γ—decreased by antipsychotics) could be used
as marker of the treatment response, since antipsychotic treatment corrected the inflammation in
schizophrenia [60].
The neurotrophin BDNF is an interesting candidate in the search for biomarkers that could improve
diagnosis and therapy monitoring in patients with schizophrenia. Most of the studies reported reduced
expression of BDNF gene and significantly decreased BDNF protein concentration in different brain areas,
and decreased concentration of plasma BDNF in patients with schizophrenia [88–90,97–100]. In contrast
to neuroendocrine and immune markers that were associated with treatment response, BDNF was
confirmed to be significantly reduced in plasma samples of schizophrenia patients, either in medicated
or in drug-naïve patients [106]. Chronic treatment with antipsychotics affected BDNF mRNA and
protein expression in both the CNS and at the periphery [106]. Significant association was reported for
BDNF Val66Met polymorphism and antipsychotic treatment response, showing that better therapeutic
response was found in carriers of the Val/Val homozygous genotype and suggesting that this genotype
might be used to predict good treatment response in schizophrenia [131–133]. Future studies should
focus on linking specific BDNF haplotype combinations with treatment response in patients with
schizophrenia [139].
However, confounding factors, such as sex, the use of oral contraceptive pills, or pre-and
postmenopausal status or phases of the menstrual cycle should be controlled, since they present
sources of variation that might significantly impact biomarker findings [385]. Besides these hormonal
variables, biomarkers should be adjusted for age, BMI, medication, but also other demographic,
lifestyle, and health variables [385]. Opposed to previous criteria [386] that included paranoid,
disorganized, catatonic, residual and undifferentiated subtypes of schizophrenia, new diagnostic
DSM-5 criteria [387] removed schizophrenia subtypes as they were associated with poor reliability,
low stability over time, and had insignificant prognostic value, and therefore did not contribute to
improved treatment or better prediction of the treatment response [388]. Due to the reduced utility
of schizophrenia subtypes and their poor diagnostic and prognostic values [388], this review did not
focus on markers or the combinations of markers that could be best suited to differentiate between
different forms or subtypes of schizophrenia.
At present, there are still no validated laboratory tests, biomarker(s) or a panel of combined
markers for schizophrenia diagnosis, prognosis or the prediction of the treatment response. Selected
serum analytes (among the 34 analytes betacellulin, bone morphogenic protein 6, eotaxin 3,
follicle stimulating hormone and epidermal growth factor were significantly altered in first-onset
antipsychotic naïve patients with schizophrenia compared to control subjects), were suggested to
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indicate a reproducible biological signature, but these studies need replication in larger population
and in longitudinal studies [389].
Despite intensive research, due to many inconsistencies among studies, no neurotransmitter
markers have been considered as valid theranostic biomarkers for schizophrenia which could
soon enter the clinical routine [390]. In addition to the components of monoamine systems,
other candidate neurotransmitter biomarkers recently received increased attention [391]. However,
there is still a limited evidence of their validity and specificity in schizophrenia, as so far these
findings have not been sufficiently reproduced in larger cohorts and independent samples [392].
Although neurotransmitter changes observed in the brain are often not accompanied with the
same patterns in the periphery, evidence suggests that they can be used as potential biomarkers
of schizophrenia treatment efficacy [17]. This refers especially for the peripheral monoamine-related
molecules that, due to their strong association with the pharmacological properties of antipsychotic
drugs, might represent good indicators of treatment response, instead of being stable trait markers
suitable for straightforward diagnosis of schizophrenia [17].
Recently [393], schizophrenia was postulated to represent altered homeostasis of immune/
inflammatory, oxidative stress, endocrine and metabolic signaling processes that mediate and affect
dopaminergic, serotonergic, glutamatergic, GABA-ergic and cholinergic neurotransmission and
white matter-associated neural connectivity. This review confirmed that neuronal connectivity is
modulated by the cross-talk among molecular markers of these systems associated with disturbances
in stress signaling, and vice versa [393]. Numerous molecular substrates, responsible for the
imbalance in homeostatic signaling, should be used to discover validated biomarkers or biomarker
test in schizophrenia.
Therefore, the future use of diagnostic, prognostic and theranostic biomarkers will improve
diagnosis, therapy monitoring, and prediction of treatment outcome [13–17]. These biomarkers,
when validated and approved for clinical practice, will improve the quality of life in patients with
schizophrenia and decrease health costs worldwide.
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CRP C-reactive protein
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DHEA dehydroepiandrosterone
DHEAS DHEA sulphate
BMI Body mass index
NGF Nerve growth factor
BDNF Brain-derived neurotrophic factor
NT-3 Neurotrophin-3
NT-4/5 Neurotrophin-4/5
p75NTR Pan neurotrophin receptor
mRNA messenger RNA
5-HTR2 Serotonergic receptor type 2
DRD2 Dopaminergic receptor type 2
NGFR NGF receptor
DA Dopamine
DR Dopamine receptor i.e., DRD2-dopamine receptor type D2
PFC Prefrontal cortex
TH Tyrosine hydroxylase
DAT Dopamine transporter
HVA Homovanillic acid
COMT Catechol-O-methyl transferase
LSD Lysergic acid diethylamide
5-HT Serotonin
5-HTT/SERT Serotonin transporter
5-HTR Serotonin receptor i.e., 5-HTR1A-serotonin receptor type 1A
MHPG 3-methoxy-4-hydroxyphenylglycol
NMDAR N-methyl-D-aspartate receptor
mGluR Metabotropic glutamate receptor i.e., mGluR3- Metabotropic glutamate receptor type 3
GABA Gamma-amino-butyric acid
GAD Glutamic acid decarboxylase
GABR GABA-A receptor gene i.e., GABRB2-GABA-A receptor beta2 subunit gene
References
1. Halldorsdottir, T.; Binder, E.B. Gene × Environment interactions: From molecular mechanisms to behavior.
Annu. Rev. Psychol. 2017, 68, 215–241. [CrossRef] [PubMed]
2. Kahn, R.S.; Sommer, I.E.; Murray, R.M.; Meyer-Lindenberg, A.; Weinberger, D.R.; Cannon, T.D.; O’Donovan, M.;
Correll, C.U.; Kane, J.M.; van Os, J.; et al. Schizophrenia. Nat. Rev. Dis. Prim. 2015, 1, 15067. [CrossRef] [PubMed]
3. Gispen-de Wied, C.C. Stress in schizophrenia: An integrative view. Eur. J. Pharmacol. 2000, 405, 375–384.
[CrossRef]
4. Mizuno, Y.; Wartelsteiner, F.; Frajo-Apor, B. Resilience research in schizophrenia: A review of recent
developments. Curr. Opin. Psychiatry 2016, 29, 218–223. [CrossRef] [PubMed]
5. McEwen, B.S. Allostasis and allostatic load: Implications for neuropsychopharmacology. Neuropsychopharmacology
2000, 22, 108–124. [CrossRef]
6. Russo, S.J.; Murroughl, J.W.; Han, M.H.; Charney, D.S.; Nestler, E.J. Neurobiology of resilience. Nat. Neurosci.
2012, 15, 1475–1484. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 18 of 38
7. Chan, M.K.; Krebs, M.-O.; Cox, D.; Guest, P.C.; Yolken, R.H.; Rahmoune, H.; Rothermundt, M.; Steiner, J.;
Leweke, F.M.; van Beveren, N.J.M.; et al. Development of a blood-based molecular biomarker test for
identification of schizophrenia before disease onset. Transl. Psychiatry 2015, 5, e601. [CrossRef] [PubMed]
8. Corcoran, C.; Mujica-Parodi, L.; Yale, S.; Leitman, D.; Malaspina, D. Could stress cause psychosis in
individuals vulnerable to schizophrenia? CNS Spectr. 2002, 7, 33–42. [CrossRef] [PubMed]
9. Walker, E.F.; Diforio, D. Schizophrenia: A neural diathesis-stress model. Psychol. Rev. 1997, 104, 667–685.
[CrossRef] [PubMed]
10. Walker, E.; Mittal, V.; Tessner, K. Stress and the hypothalamic pituitary adrenal axis in the developmental
course of schizophrenia. Annu. Rev. Clin. Psychol. 2008, 4, 189–216. [CrossRef] [PubMed]
11. Pruessner, M.; Cullen, A.E.; Aas, M.; Walker, E.F. The neural diathesis-stress model of schizophrenia revisited:
An update on recent findings considering illness stage and neurobiological and methodological complexities.
Neurosci. Biobehav. Rev. 2016, 73, 191–218. [CrossRef] [PubMed]
12. Hutson, P.H.; Clark, J.A.; Cross, A.J. CNS target identification and validation: Avoiding the valley of death
or naive optimism? Annu. Rev. Pharmacol. Toxicol. 2017, 57, 171–187. [CrossRef] [PubMed]
13. Weickert, C.S.; Weickert, T.W.; Pillai, A.; Buckley, P.F. Biomarkers in Schizophrenia: A Brief Conceptual
Consideration. Dis. Markers 2013, 35, 3–9. [CrossRef] [PubMed]
14. Steiner, J.; Guest, P.C.; Rahmoune, H.; De-Souza, D.M. The application of multiplex biomarker techniques
for improved stratification and treatment of schizophrenia patients. Methods Mol. Biol. 2017, 1546, 19–35.
[PubMed]
15. Chan, M.K.; Gottschalk, M.G.; Haenisch, F.; Tomasik, J.; Ruland, T.; Rahmoune, H.; Guest, P.C.; Bahn, S.
Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog. Neurobiol.
2014, 122, 45–72. [CrossRef] [PubMed]
16. Scarr, E.; Millan, M.J.; Bahn, S.; Bertolino, A.; Turck, C.W.; Kapur, S.; Möller, H.J.; Dean, B. Biomarkers for
psychiatry: The journey from fantasy to fact, a report of the 2013 CINP Think Tank. Int. J. Neuropsychopharmacol.
2015, 18, pyv042. [CrossRef] [PubMed]
17. Lai, C.-Y.; Scarr, E.; Udawela, M.; Everall, I.; Chen, W.J.; Dean, B. Biomarkers in schizophrenia: A focus on
blood based diagnostics and theranostics. World J. Psychiatry 2016, 6, 102–117. [CrossRef] [PubMed]
18. Xie, J.; Lee, S.; Chen, X. Nanoparticle-based theranostic agents. Adv. Drug Deliv. Rev. 2010, 62, 1064–1079.
[CrossRef] [PubMed]
19. Harris, L.W.; Pietsch, S.; Cheng, T.M.K.; Schwarz, E.; Guest, P.C.; Bahn, S. Comparison of peripheral and
central schizophrenia biomarker profiles. PLoS ONE 2012, 7, e46368. [CrossRef] [PubMed]
20. Yolken, R.H.; Torrey, E.F. Are some cases of psychosis caused by microbial agents? A review of the evidence.
Mol. Psychiatry 2008, 13, 470–479. [CrossRef] [PubMed]
21. Suvisaari, J.; Loo, B.M.; Saarni, S.E.; Haukka, J.; Perala, J.; Saarni, S.I.; Viertio, S.; Partti, K.; Lonnqvist, J.;
Jula, A. Inflammation in psychotic disorders: A population-based study. Psychiatry Res. 2011, 189, 305–311.
[CrossRef] [PubMed]
22. Singh, B.; Chaudhuri, T.K. Role of c-reactive protein in schizophrenia: An overview. Psychiatry Res. 2014,
216, 277–285. [CrossRef] [PubMed]
23. Fineberg, A.M.; Ellman, L.M. Inflammatory cytokines and neurological and neurocognitive alterations in the
course of schizophrenia. Biol. Psychiatry 2013, 73, 951–966. [CrossRef] [PubMed]
24. Benros, M.E.; Nielsen, P.R.; Nordentoft, M.; Eaton, W.W.; Dalton, S.O.; Mortensen, P.B. Autoimmune
diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study.
Am. J. Psychiatry 2011, 168, 1303–1310. [CrossRef] [PubMed]
25. Corvin, A.; Morris, D.W. Genome-wide association studies: Findings at the major histocompatibility complex
locus in psychosis. Biol. Psychiatry 2014, 75, 276–283. [CrossRef] [PubMed]
26. Dickerson, F.; Stallings, C.; Origoni, A.; Vaughan, C.; Khushalani, S.; Yang, S.J.; Yolken, R. C-reactive protein
is elevated in schizophrenia. Schizophr. Res. 2013, 143, 198–202. [CrossRef] [PubMed]
27. Miller, B.J.; Culpepper, N.; Rapaport, M.H. C-reactive protein levels in schizophrenia: A review and
meta-analysis. Clin. Schizophr. Relat. Psychoses 2014, 7, 223–230. [CrossRef] [PubMed]
28. Fan, X.D.; Pristach, C.; Liu, E.Y.; Freudenreich, O.; Henderson, D.C.; Goff, D.C. Elevated serum levels
of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with
schizophrenia. Psychiatry Res. 2007, 149, 267–271. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 19 of 38
29. Fawzi, M.H.; Fawzi, M.M.; Fawzi, M.M.; Said, N.S. C-reactive protein serum level in drug-free male egyptian
patients with schizophrenia. Psychiatry Res. 2011, 190, 91–97. [CrossRef] [PubMed]
30. Vuksan-Cusa, B.; Sagud, M.; Jakovljevic, M. C-reactive protein and metabolic syndrome in patients with
bipolar disorder compared to patients with schizophrenia. Psychiatr. Danub. 2010, 22, 275–277. [PubMed]
31. Hope, S.; Melle, I.; Aukrust, P.; Steen, N.E.; Birkenaes, A.B.; Lorentzen, S.; Agartz, I.; Ueland, T.;
Andreassen, O.A. Similar immune profile in bipolar disorder and schizophrenia: Selective increase in
soluble tumor necrosis factor receptor I and von willebrand factor. Bipolar Disord. 2009, 11, 726–734.
[CrossRef] [PubMed]
32. Baptista, T.; Davila, A.; El Fakih, Y.; Uzcategui, E.; Rangel, N.N.; Olivares, Y.; Galeazzi, T.; Vargas, D.; Pena, R.;
Marquina, D.; et al. Similar frequency of abnormal correlation between serum leptin levels and bmi before
and after olanzapine treatment in schizophrenia. Int. Clin. Psychopharmacol. 2007, 22, 205–211. [CrossRef]
[PubMed]
33. Miller, B.J.; Buckley, P.; Seabolt, W.; Mellor, A.; Kirkpatrick, B. Meta-analysis of cytokine alterations in
schizophrenia: Clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70, 663–671. [CrossRef]
[PubMed]
34. De Witte, L.; Tomasik, J.; Schwarz, E.; Guest, P.C.; Rahmoune, H.; Kahn, R.S.; Bahn, S. Cytokine alterations in
first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr. Res. 2014, 154, 23–29.
[CrossRef] [PubMed]
35. Schwarz, E.; Guest, P.C.; Rahmoune, H.; Martins-de-Souza, D.; Niebuhr, D.W.; Weber, N.S.; Cowan, D.N.;
Yolken, R.H.; Spain, M.; Barnes, A.; et al. Identification of a blood-based biological signature in subjects with
psychiatric disorders prior to clinical manifestation. World J. Biol. Psychiatry 2012, 13, 627–632. [CrossRef]
[PubMed]
36. Schwarz, E.; Guest, P.C.; Steiner, J.; Bogerts, B.; Bahn, S. Identification of blood-based molecular signatures
for prediction of response and relapse in schizophrenia patients. Transl. Psychiatry 2012, 2, e82. [CrossRef]
[PubMed]
37. Ellman, L.M.; Yolken, R.H.; Buka, S.L.; Torrey, E.F.; Cannon, T.D. Cognitive functioning prior to the onset of
psychosis: The role of fetal exposure to serologically determined influenza infection. Biol. Psychiatry 2009, 65,
1040–1047. [CrossRef] [PubMed]
38. Brown, A.S.; Cohen, P.; Harkavy-Friedman, J.; Babulas, V.; Malaspina, D.; Gorman, J.M.; Susser, E.S. Prenatal
rubella, premorbid abnormalities, and adult schizophrenia. Biol. Psychiatry 2001, 49, 473–486. [CrossRef]
39. Suvisaari, J.; Haukka, J.; Tanskanen, A.; Hovi, T.; Lonnqvist, J. Association between prenatal exposure to
poliovirus infection and adult schizophrenia. Am. J. Psychiatry 1999, 156, 1100–1102. [PubMed]
40. Torrey, E.F.; Rawlings, R.; Waldman, I.N. Schizophrenic births and viral diseases in 2 states. Schizophr. Res.
1988, 1, 73–77. [CrossRef]
41. Buka, S.L.; Tsuang, M.T.; Torrey, E.F.; Klebanoff, M.A.; Bernstein, D.; Yolken, R.H. Maternal infections and
subsequent psychosis among offspring. Arch. Gen. Psychiatry 2001, 58, 1032–1037. [CrossRef] [PubMed]
42. Mortensen, P.B.; Norgaard-Pedersen, B.; Waltoft, B.L.; Sorensen, T.L.; Hougaard, D.; Yolken, R.H. Early
infections of toxoplasma gondii and the later development of schizophrenia. Schizophr. Bull. 2007, 33,
741–744. [CrossRef] [PubMed]
43. Patterson, P.H. Immune involvement in schizophrenia and autism: Etiology, pathology and animal models.
Behav. Brain. Res. 2009, 204, 313–321. [CrossRef] [PubMed]
44. Buka, S.L.; Tsuang, M.T.; Torrey, E.F.; Klebanoff, M.A.; Wagner, R.L.; Yolken, R.H. Maternal cytokine levels
during pregnancy and adult psychosis. Brain Behav. Immun. 2001, 15, 411–420. [CrossRef] [PubMed]
45. Brown, A.S.; Hooton, J.; Schaefer, C.A.; Zhang, H.; Petkova, E.; Babulas, V.; Perrin, M.; Gorman, J.M.;
Susser, E.S. Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring.
Am. J. Psychiatry 2004, 161, 889–895. [CrossRef] [PubMed]
46. Ellman, L.M.; Deicken, R.F.; Vinogradov, S.; Kremen, W.S.; Poole, J.H.; Kern, D.M.; Tsai, W.Y.; Schaefer, C.A.;
Brown, A.S. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory
cytokine interleukin-8. Schizophr. Res. 2010, 121, 46–54. [CrossRef] [PubMed]
47. Wright, I.C.; Rabe-Hesketh, S.; Woodruff, P.W.R.; David, A.S.; Murray, R.M.; Bullmore, E.T. Meta-analysis of
regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157, 16–25. [CrossRef] [PubMed]
48. Ezeoke, A.; Mellor, A.; Buckley, P.; Miller, B. A systematic, quantitative review of blood autoantibodies in
schizophrenia. Schizophr. Res. 2013, 150, 245–251. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 20 of 38
49. Brey, R.L.; Holliday, S.I.; Saklad, A.R.; Navarrete, M.G.; Hermosillo-Romo, D.; Stallworth, C.L.; Valdez, C.R.;
Escalante, A.; del Rincon, I.; Gronseth, G.; et al. Neuropsychiatric syndromes in lupus—Prevalence using
standarized definitions. Neurology 2002, 58, 1214–1220. [CrossRef] [PubMed]
50. Tsuang, M. Schizophrenia: Genes and environment. Biol. Psychiatry 2000, 47, 210–220. [CrossRef]
51. Bergen, S.E.; O’Dushlaine, C.T.; Ripke, S.; Lee, P.H.; Ruderfer, D.M.; Akterin, S.; Moran, J.L.; Chambert, K.D.;
Handsaker, R.E.; Backlund, L.; et al. Genome-wide association study in a swedish population yields support
for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Mol. Psychiatry
2012, 17, 880–886. [CrossRef] [PubMed]
52. Beck, S.; Geraghty, D.; Inoko, H.; Rowen, L.; Aguado, B.; Bahram, S.; Campbell, R.D.; Forbes, S.A.;
Guillaudeux, T.; Hood, L.; et al. Complete sequence and gene map of a human major histocompatibility
complex. Nature 1999, 401, 921–923.
53. Smoller, J.W.; Craddock, N.; Kendler, K.; Lee, P.H.; Neale, B.M.; Nurnberger, J.I.; Ripke, S.; Santangelo, S.;
Sullivan, P.F.; Fanous, A.; et al. Identification of risk loci with shared effects on five major psychiatric
disorders: A genome-wide analysis. Lancet 2013, 381, 1371–1379.
54. Sinkus, M.L.; Adams, C.E.; Logel, J.; Freedman, R.; Leonard, S. Expression of immune genes on chromosome
6p21.3-22.1 in schizophrenia. Brain Behav. Immun. 2013, 32, 51–62. [CrossRef] [PubMed]
55. Sommer, I.E.; de Witte, L.; Begemann, M.; Kahn, R.S. Nonsteroidal anti-inflammatory drugs in schizophrenia:
Ready for practice or a good start? A meta-analysis. J. Clin. Psychiatry 2012, 73, 414–419. [CrossRef]
[PubMed]
56. Laan, W.; Grobbee, D.E.; Selten, J.P.; Heijnen, C.J.; Kahn, R.S.; Burger, H. Adjuvant aspirin therapy
reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind,
placebo-controlled trial. J. Clin. Psychiatry 2010, 71, 520–527. [CrossRef] [PubMed]
57. El-Sisi, A.E.; Sokkar, S.S.; El-Sayad, M.E.; Ramadan, E.S.; Osman, E.Y. Celecoxib andω-3 fatty acids alone
and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced
model of schizophrenia. Biomed. Pharmacother. 2016, 82, 425–431. [CrossRef] [PubMed]
58. Mondelli, V.; Ciufolini, S.; Murri, M.B.; Bonaccorso, S.; Di Forti, M.; Giordano, A.; Marques, T.R.;
Zunszain, P.A.; Morgan, C.; Murray, R.M.; et al. Cortisol and inflammatory biomarkers predict poor
treatment response in first episode psychosis. Schizophr. Bull. 2015, 41, 1162–1170. [CrossRef] [PubMed]
59. Fond, G.; Boyer, L.; Gaman, A.; Laouamri, H.; Attiba, D.; Richard, J.R.; Delavest, M.; Houenou, J.;
Le Corvoisier, P.; Charron, D.; et al. Treatment with anti-toxoplasmic activity (TATA) for toxoplasma
positive patients with bipolar disorders or schizophrenia: A cross-sectional study. J. Psychiatr. Res. 2015, 63,
58–64. [CrossRef] [PubMed]
60. Tourjman, V.; Kouassi, E.; Koue, M.E.; Rocchetti, M.; Fortin-Fournier, S.; Fusar-Poli, P.; Potvin, S.
Antipsychotics’ effects on blood levels of cytokines in schizophrenia: A meta-analysis. Schizophr. Res.
2013, 151, 43–47. [CrossRef] [PubMed]
61. Song, X.Q.; Fan, X.D.; Li, X.; Zhang, W.; Gao, J.S.; Zhao, J.P.; Harrington, A.; Ziedonis, D.; Lv, L.X. Changes
in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naive,
first-episode schizophrenia. Psychopharmacology 2014, 231, 319–325. [CrossRef] [PubMed]
62. Hori, H.; Teraishi, T.; Sasayama, D.; Fujii, T.; Hattori, K.; Ishikawa, M.; Kunugi, H. Elevated cortisol level
and cortisol/DHEAS ratio in schizophrenia as revealed by low-dose dexamethasone suppression test.
Open Neuropsychopharmacol. J. 2012, 5, 18–24. [CrossRef]
63. Jakovljevic, M.; Muck-Seler, D.; Pivac, N.; Crncevic, Z. Platelet 5-HT and plasma cortisol concentrations after
dexamethasone suppression test in patients with different time course of schizophrenia. Neuropsychobiology
1998, 37, 142–145. [CrossRef] [PubMed]
64. Mondelli, V.; Dazzan, P.; Hepgul, N.; Di Forti, M.; Aas, M.; D’Albenzio, A.; Di Nicola, M.; Fisher, H.;
Handley, R.; Marques, T.R.; et al. Abnormal cortisol levels during the day and cortisol awakening response in
first-episode psychosis: The role of stress and of antipsychotic treatment. Schizophr. Res. 2010, 116, 234–242.
[CrossRef] [PubMed]
65. Muck-Seler, D.; Pivac, N.; Jakovljevic, M.; Brzovic, Z. Platelet serotonin, plasma cortisol, and dexamethasone
suppression test in schizophrenic patients. Biol. Psychiatry 1999, 45, 1433–1439. [CrossRef]
66. Girshkin, L.; Matheson, S.L.; Shepherd, A.M.; Green, M.J. Morning cortisol levels in schizophrenia and
bipolar disorder: A meta-analysis. Psychoneuroendocrinology 2014, 49, 187–206. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 21 of 38
67. Guest, P.C.; Schwarz, E.; Krishnamurthy, D.; Harris, L.W.; Leweke, F.M.; Rothermundt, M.; van Beveren, N.J.;
Spain, M.; Barnes, A.; Steiner, J.; et al. Altered levels of circulating insulin and other neuroendocrine
hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 2011, 36, 1092–2096.
[CrossRef] [PubMed]
68. Murri, M.B.; Pariante, C.M.; Dazzan, P.; Hepgul, N.; Papadopoulos, A.S.; Zunszain, P.; Di Forti, M.;
Murray, R.M.; Mondelli, V. Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode
psychosis. Psychoneuroendocrinology 2012, 37, 629–644. [CrossRef] [PubMed]
69. Girshkin, L.; O’Reilly, N.; Quide, Y.; Teroganova, N.; Rowland, J.E.; Schofield, P.R.; Green, M.J.
Diurnal cortisol variation and cortisol response to an MRI stressor in schizophrenia and bipolar disorder.
Psychoneuroendocrinology 2016, 67, 61–69. [CrossRef] [PubMed]
70. Bradley, A.J.; Dinan, T.G. A systematic review of hypothalamic-pituitary-adrenal axis function in
schizophrenia: Implications for mortality. J. Psychopharmacol. 2010, 24, 91–118. [CrossRef] [PubMed]
71. Roy, A.; Pickar, D.; Doran, A.; Wolkowitz, O.; Gallucci, W.; Chrousos, G.; Gould, P. The corticotropin-releasing
hormone stimulation test in chronic schizophrenia. Am. J. Psychiatry 1986, 143, 1393–1397. [PubMed]
72. Lammers, C.H.; Garcia-Borreguero, D.; Schmider, J.; Gotthardt, U.; Dettling, M.; Holsboer, F.; Heuser, I.J.
Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in
normal controls: II. Biol. Psychiatry 1995, 38, 803–807. [CrossRef]
73. Gallagher, P.; Watson, S.; Smith, M.S.; Young, A.H.; Ferrier, I.N. Plasma cortisol-dehydroepiandrosterone
(DHEA) ratios in schizophrenia and bipolar disorder. Schizophr. Res. 2007, 90, 258–265. [CrossRef] [PubMed]
74. Brenner, K.; Liu, A.; Laplante, D.P.; Lupien, S.; Pruessner, J.C.; Ciampi, A.; Joober, R.; King, S. Cortisol
response to a psychosocial stressor in schizophrenia: Blunted, delayed, or normal? Psychoneuroendocrinology
2009, 34, 859–868. [CrossRef] [PubMed]
75. Jakovljevic, M.; Pivac, N.; Mihaljevic-Peles, A.; Mustapic, M.; Relja, M.; Ljubicic, D.; Marcinko, D.;
Muck-Seler, D. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity
in schizophrenic patients: A double blind study. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2007, 1,
399–402. [CrossRef] [PubMed]
76. Zannas, A.S.; Wiechmann, T.; Gassen, N.C.; Binder, E.B. Gene-stress-epigenetic regulation of FKBP5: Clinical
and translational implications. Neuropsychopharmacology 2016, 41, 261–274. [CrossRef] [PubMed]
77. Bevilacqua, L.; Carli, V.; Sarchiapone, M.; George, D.K.; Goldman, D.; Roy, A.; Enoch, M.A. Interaction
between FKBP5 and childhood trauma and risk of aggressive behavior. Arch. Gen. Psychiatry 2012, 69, 62–70.
[CrossRef] [PubMed]
78. Collip, D.; Myin-Germeys, I.; Wichers, M.; Jacobs, N.; Derom, C.; Thiery, E.; Lataster, T.; Simons, C.;
Delespaul, P.; Marcelis, M.; et al. FKBP5 as a possible moderator of the psychosis-inducing effects of
childhood trauma. Br. J. Psychiatry 2013, 202, 261–268. [CrossRef] [PubMed]
79. Pereira, M.J.; Palming, J.; Svensson, M.K.; Rizell, M.; Dalenback, J.; Hammar, M.; Fall, T.; Sidibeh, C.O.;
Svensson, P.A.; Eriksson, J.W. FKBP5 expression in human adipose tissue increases following dexamethasone
exposure and is associated with insulin resistance. Metabolism 2014, 63, 1198–1208. [CrossRef] [PubMed]
80. De Luca, V.; Tharmalingam, S.; Zai, C.; Potapova, N.; Strauss, J.; Vincent, J.; Kennedy, J.L. J. Psychopharmacol.
2010, 24, 677–682. [PubMed]
81. Ryan, M.C.; Thakore, J.H. Physical consequences of schizophrenia and its treatment: The metabolic syndrome.
Life Sci. 2002, 71, 239–257. [CrossRef]
82. De Hert, M.; Schreurs, W.; Vancampfort, D.; Van Winkel, R. Metabolic syndrome in people with schizophrenia:
A review. World Psychiatry 2009, 8, 15–22. [CrossRef] [PubMed]
83. Akiibinu, M.O.; Ogundahunsi, O.A.; Ogunyemi, E.O. Inter-relationship of plasma markers of oxidative
stress and thyroid hormones in schizophrenics. BMC Res. Notes 2012, 5, 169. [CrossRef] [PubMed]
84. Vuksan Cusa, B.; Sagud, M.; Rados, I. The role of dehydroepiandrosterone (DHEA) in schizophrenia.
Psychiatr. Danub. 2016, 28, 30–33. [PubMed]
85. Matsumoto, T.; Rauskolb, S.; Polack, M.; Klose, J.; Kolbeck, R.; Korte, M.; Barde, Y.A. Biosynthesis and
processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat. Neurosci. 2008,
11, 131–133. [CrossRef] [PubMed]
86. Huang, E.J.; Reichardt, L.F. Trk receptors: Roles in signal transduction. Annu. Rev. Biochem. 2003, 72, 609–642.
[CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 22 of 38
87. Marenco, S.; Weinberger, D.R. The neurodevelopmental hypothesis of schizophrenia: Following a trail of
evidence from cradle to grave. Dev. Psychopathol. 2000, 12, 501–527. [CrossRef] [PubMed]
88. Thompson Ray, M.; Weickert, C.S.; Wyatt, E.; Webster, M.J. Decreased BDNF, TrkB-TK+ and GAD67 mRNA
expression in the hippocampus of individuals with schizophrenia and mood disorders. J. Psychiatry Neurosci.
2011, 36, 195–203. [CrossRef] [PubMed]
89. Durany, N.; Michel, T.; Zöchling, R.; Boissl, K.W.; Cruz-Sánchez, F.F.; Riederer, P.; Riederer, P.; Thome, J.
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr. Res. 2001, 52,
79–86. [CrossRef]
90. Issa, G.; Wilson, C.; Terry, A.V., Jr.; Pillai, A. An inverse relationship between cortisol and BDNF level
in schizophrenia: Data from human postmortem and animal studies. Neurobiol. Dis. 2010, 39, 327–333.
[CrossRef] [PubMed]
91. Yamamoto, H.; Gurnay, M.E. Human platelets contain brain-derived neurotrophic factor. J. Neurosci. 1990,
10, 3469–3478. [PubMed]
92. Colombo, E.; Bedogni, F.; Lorenzetti, I.; Landsberger, N.; Previtali, S.C.; Farina, C. Autocrine and immune
cell-derived BDNF in human skeletal muscle: Implications for myogenesis and tissue regeneration. J. Pathol.
2013, 231, 190–198. [CrossRef] [PubMed]
93. Pan, W.; Banks, W.A.; Fasold, M.B.; Bluth, J.; Kastin, A.J. Transport of brain-derived neurotrophic factor
across the blood-brain barrier. Neuropharmacology 1998, 37, 1553–1561. [CrossRef]
94. Nurjono, M.; Lee, J.; Chong, S.A. A review of brain-derived neurotrophic factor as a candidate biomarker in
Schizophrenia. Clin. Psychopharmacol. Neurosci. 2012, 10, 61–70. [CrossRef] [PubMed]
95. Karege, F.; Schwald, M.; Cisse, M. Postnatal developmental profile of brain-derived neurotrophic factor in
rat brain and platelets. Neurosci. Lett. 2002, 328, 261–264. [CrossRef]
96. Klein, A.B.; Williamson, R.; Santini, M.A.; Clemmensen, C.; Ettrup, A.; Rios, M.; Knudsen, G.M.; Aznar, S.
Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int. J. Neuropsychopharmacol.
2011, 14, 347–353. [CrossRef] [PubMed]
97. Chen, D.; Wang, J.; Wang, B.; Yang, S.C.; Zhang, C.X.; Zheng, Y.L.; Li, Y.L.; Wang, N.; Yang, K.B.;
Xiu, M.H.; et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode
schizophrenia: Relationship to clinical phenotypes. Psychopharmacol. Berl. 2009, 207, 375–380. [CrossRef]
[PubMed]
98. Jindal, R.D.; Pillai, A.K.; Mahadik, S.P.; Eklund, K.; Montrose, D.M.; Keshavan, M.S. Decreased BDNF in
patients with antipsychotic naïve first episode schizophrenia. Schizophr. Res. 2010, 119, 47–51. [CrossRef]
[PubMed]
99. Pirildar, S¸.; Gönül, A.S.; Taneli, F.; Akdeniz, F. Low serum levels of brain-derived neurotrophic factor
in patients with schizophrenia do not elevate after antipsychotic treatment. Prog. Neuropsychopharmacol.
Biol. Psychiatry 2004, 28, 709–713. [CrossRef] [PubMed]
100. Rizos, E.N.; Rontos, I.; Laskos, E.; Arsenis, G.; Michalopoulou, P.G.; Vasilopoulos, D.; Gournellis, R.; Lykouras, L.
Investigation of serum BDNF levels in drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol.
Biol. Psychiatry 2008, 32, 1308–1311. [CrossRef] [PubMed]
101. Grillo, R.W.; Ottoni, G.L.; Leke, R.; Souza, D.O.; Portela, L.V.; Lara, D.R. Reduced serum BDNF levels in
schizophrenic patients on clozapine or typical antipsychotics. J. Psychiatr. Res. 2007, 41, 31–35. [CrossRef]
[PubMed]
102. Tan, Y.L.; Zhou, D.F.; Cao, L.Y.; Zou, Y.Z.; Zhang, X.Y. Decreased BDNF in serum of patients with chronic
schizophrenia on long-term treatment with antipsychotics. Neurosci. Lett. 2005, 382, 27–32. [CrossRef]
[PubMed]
103. Toyooka, K.; Asama, K.; Watanabe, Y.; Muratake, T.; Takahashi, M.; Someya, T.; Nawa, H. Decreased levels
of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002, 110,
249–257. [CrossRef]
104. Zhang, X.Y.; Tan, Y.L.; Zhou, D.F.; Cao, L.Y.; Wu, G.Y.; Xu, Q.; Shen, Y.; Haile, C.N.; Kosten, T.A.; Kosten, T.R.
Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics.
J. Psychiatr. Res. 2007, 41, 997–1004. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 23 of 38
105. Xiu, M.H.; Hui, L.; Dang, Y.F.; Hou, T.D.; Zhang, C.X.; Zheng, Y.L.; Chen, D.C.; Kosten, T.R.; Zhang, X.Y.
Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical
and atypical antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 1508–1512. [CrossRef]
[PubMed]
106. Green, M.J.; Matheson, S.L.; Shepherd, A.; Weickert, C.S.; Carr, V.J. Brain-derived neurotrophic factor levels
in schizophrenia: A systematic review with meta-analysis. Mol. Psychiatry 2011, 16, 960–972. [CrossRef]
[PubMed]
107. Pedrini, M.; Chendo, I.; Grande, I.; Lobato, M.I.; Belmontede-Abreu, P.S.; Lersch, C.; Walz, J.;
Kauer-Sant’anna, M.; Kapczinski, F.; Gama, C.S. Serum brain-derived neurotrophic factor and clozapine daily
dose in patients with schizophrenia: A positive correlation. Neurosci. Lett. 2011, 491, 207–210. [CrossRef]
[PubMed]
108. Carlino, D.; Leone, E.; Di Cola, F.; Baj, G.; Marin, R.; Dinelli, G.; Tongiorgi, E.; De Vanna, M. Low serum
truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J. Psychiatr. Res.
2011, 45, 273–279. [CrossRef] [PubMed]
109. Angelucci, F.; Mathe, A.A.; Aloe, L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in
rat brain are significantly altered after haloperidol and risperidone administration. J. Neurosci. Res. 2000, 60,
783–794. [CrossRef]
110. Dawson, N.M.; Hamid, E.H.; Egan, M.F.; Meredith, G.E. Changes in the pattern of brain-derived neurotrophic
factor immunoreactivity in the rat brain after acute and subchronic haloperidol treatment. Synapse 2001, 39,
70–81. [CrossRef]
111. Lipska, B.K.; Khaing, Z.Z.; Weickert, C.S.; Weinberger, D.R. BDNF mRNA expression in rat hippocampus and
prefrontal cortex: Effects of neonatal ventral hippocampal damage and antipsychotic drugs. Eur. J. Neurosci.
2001, 14, 135–144. [CrossRef] [PubMed]
112. Parikh, V.; Khan, M.M.; Mahadik, S.P. Olanzapine counteracts reduction of brain-derived neurotrophic
factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci. Lett. 2004, 356, 135–139.
[CrossRef] [PubMed]
113. Chlan-Fourney, J.; Ashe, P.; Nylen, K.; Juorio, A.V.; Li, X.M. Differential regulation of hippocampal BDNF
mRNA by typical and atypical antipsychotic administration. Brain Res. 2002, 954, 11–20. [CrossRef]
114. Egan, M.F.; Kojima, M.; Callicott, J.H.; Goldberg, T.E.; Kolachana, B.S.; Bertolino, A.; Zaitsev, E.; Gold, B.;
Goldman, D.; Dean, M.; et al. The BDNF Val66met polymorphism affects activity-dependent secretion of
BDNF and human memory and hippocampal function. Cell 2003, 112, 257–269. [CrossRef]
115. Chen, Z.-Y.; Ieraci, A.; Teng, H.; Dall, H.; Meng, C.-X.; Herrera, D.G.; Nykjaer, A.; Hemp-stead, B.L.; Lee, F.S.
Sortilin controls intracellular sorting of brain-derived neurotrophic factor to the regulated secretory pathway.
J. Neurosci. 2005, 25, 6156–6166. [CrossRef] [PubMed]
116. Dayem Ullah, A.Z.; Lemoine, N.R.; Chelala, C. SNPnexus: A web server for functional annotation of novel
and publicly known genetic variants (2012 update). Nucleic Acids Res. 2012, 40, W65–W70. [CrossRef]
[PubMed]
117. Zakharyan, R.; Boyajyan, A.; Arakelyan, A.; Gevorgyan, A.; Mrazek, F.; Petrek, M. Functional variants of
the genes involved in neurodevelopment and susceptibility to schizophrenia in an Armenian population.
Hum. Immunol. 2011, 72, 746–748. [CrossRef] [PubMed]
118. Gratacòs, M.; González, J.R.; Mercader, J.M.; de Cid, R.; Urretavizcaya, M.; Estivill, X. Brain-derived
neurotrophic factor Val66Met and psychiatric disorders: Meta-analysis of case–control studies confirm
association to substance-related disorders, eating disorders, and schizophrenia. Biol. Psychiatry 2007, 61,
911–922. [CrossRef] [PubMed]
119. Smith, G.N.; Thornton, A.E.; Lang, D.J.; MacEwan, G.W.; Ehmann, T.S.; Kopala, L.C.; Tee, K.; Shiau, G.;
Voineskos, A.N.; Kennedy, J.L.; et al. Hippocampal volume and the brain-derived neurotrophic factor
Val66Met polymorphism in first episode psychosis. Schizophr. Res. 2012, 134, 253–259. [CrossRef] [PubMed]
120. Neves-Pereira, M.; Cheung, J.K.; Pasdar, A.; Zhang, F.; Breen, G.; Yates, P.; Sinclair, M.; Crombie, C.; Walker, N.;
St. Clair, D.M. BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol. Psychiatry 2005, 10,
208–212. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 24 of 38
121. Rosa, A.; Cuesta, M.J.; Fatjó-Vilas, M.; Peralta, V.; Zarzuela, A.; Fañanás, L. The Val66Met polymorphism
of the brain-derived neurotrophic factor gene is associated with risk for psychosis: Evidence from
a family-based association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006, 141B, 135–138. [CrossRef]
[PubMed]
122. Chang, H.-A.; Lu, R.-B.; Shy, M.-J.; Chang, C.-C.; Lee, M.-S.; Huang, S.-Y. Brain-derived neurotrophic
factor Val66Met polymorphism: Association with psychopathological symptoms of schizophrenia?
J. Neuropsychiatry Clin. Neurosci. 2009, 21, 30–37. [CrossRef] [PubMed]
123. Jönsson, E.G.; Edman-Ahlbom, B.; Sillen, A.; Gunnar, A.; Kulle, B.; Frigessi, A.; Vares, M.; Ekholm, B.;
Wode-Helgodt, B.; Schumacher, J.; et al. Brain-derived neurotrophic factor gene (BDNF) variants and
schizophrenia: An association study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30, 924–933.
[CrossRef] [PubMed]
124. Kawashima, K.; Ikeda, M.; Kishi, T.; Kitajima, T.; Yamanouchi, Y.; Kinoshita, Y.; Okochi, T.; Aleksic, B.;
Tomita, M.; Okada, T.; et al. BDNF is not associated with schizophrenia: Data from a Japanese population
study and meta-analysis. Schizophr. Res. 2009, 112, 72–79. [CrossRef] [PubMed]
125. Zhou, D.H.; Yan, Q.Z.; Yan, X.M.; Li, C.B.; Fang, H.; Zheng, Y.L.; Zhang, C.X.; Yao, H.J.; Chen da, C.;
Xiu, M.H.; et al. The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients.
Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 930–933. [CrossRef] [PubMed]
126. Zintzaras, E. Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: A meta-analysis.
Psychiatr. Genet. 2007, 17, 69–75. [CrossRef] [PubMed]
127. Watanabe, Y.; Nunokawa, A.; Someya, T. Association of the BDNF C270T polymorphism with schizophrenia:
Updated meta-analysis. Psychiatry Clin. Neurosci. 2013, 67, 123–125. [CrossRef] [PubMed]
128. Nanko, S.; Kunugi, H.; Hirasawa, H.; Kato, N.; Nabika, T.; Kobayashi, S. Brain-derived neurotrophic factor
gene and schizophrenia: Polymorphism screening and association analysis. Schizophr. Res. 2003, 62, 281–283.
[PubMed]
129. Szekeres, G.; Juhász, A.; Rimanóczy, A.; Kéri, S.; Janka, Z. The C270T polymorphism of the brain-derived
neurotrophic factor gene is associated with schizophrenia. Schizophr. Res. 2003, 65, 15–18. [CrossRef]
130. Xu, M.Q.; St Clair, D.; Ott, J.; Feng, G.Y.; He, L. Brain-derived neurotrophic factor gene C-270T and
Val66Met functional polymorphisms and risk of schizophrenia: A moderate-scale population-based study
and meta-analysis. Schizophr. Res. 2007, 91, 6–13. [CrossRef] [PubMed]
131. Hong, C.J.; Yu, Y.W.; Lin, C.H.; Tsai, S.J. An association study of a brain-derived neurotrophic factor
Val66Met polymorphism and clozapine response of schizophrenic patients. Neurosci. Lett. 2003, 349, 206–208.
[CrossRef]
132. Zai, G.C.; Chowdhury, N.I.; Tiwari, A.K.; Souza, R.P.; Lieberman, J.A.; Meltzer, H.Y.; Potkin, S.G.; Müller, D.J.;
Kennedy, J.L. The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response
and antipsychotic-induced weight gain. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39, 96–101.
[CrossRef] [PubMed]
133. Nikolac Perkovic, M.; Nedic Erjavec, G.; Zivkovic, M.; Sagud, M.; Uzun, S.; Mihaljevic-Peles, A.; Kozumplik, O.;
Muck-Seler, D.; Pivac, N. Association between the brain-derived neurotrophic factor Val66Met polymorphism
and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacology 2014, 231, 3757–3764.
[CrossRef] [PubMed]
134. Mitjans, M.; Catalán, R.; Vázquez, M.; González-Rodríguez, A.; Penadés, R.; Pons, A.; Massana, G.; Munro, J.;
Arranz, M.J.; Arias, B. Hypothalamic-pituitary-adrenal system, neurotrophic factors and clozapine response:
Association with FKBP5 and NTRK2 genes. Pharmacogenet. Genom. 2015, 25, 274–277. [CrossRef] [PubMed]
135. Terzic, T.; Kastelic, M.; Dolzan, V.; Plesnicar, B.K. Genetic variability testing of neurodevelopmental genes in
schizophrenic patients. J. Mol. Neurosci. 2015, 56, 205–211. [CrossRef] [PubMed]
136. Xu, M.Q.; St Clair, D.; Feng, G.Y.; Lin, Z.G.; He, G.; Li, X.; He, L. BDNF gene is a genetic risk factor for
schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese
population. Pharmacogenet. Genom. 2008, 18, 449–457. [CrossRef] [PubMed]
137. Zhang, X.Y.; Zhou, D.F.; Wu, G.Y.; Cao, L.Y.; Tan, Y.L.; Haile, C.N.; Li, J.; Lu, L.; Kosten, T.A.; Kosten, T.R.
BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic
schizophrenia. Neuropsychopharmacology 2008, 33, 2200–2205. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 25 of 38
138. Tsai, A.; Liou, Y.J.; Hong, C.J.; Wu, C.L.; Tsai, S.J.; Bai, Y.M. Association study of brain-derived neurotrophic
factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical
antipsychotic treatment. Neuromol. Med. 2011, 13, 328–333. [CrossRef] [PubMed]
139. Cargnin, S.; Massarotti, A.; Terrazzino, S. BDNF Val66Met and clinical response to antipsychotic drugs:
A systematic review and meta-analysis. Eur. Psychiatry 2016, 33, 45–53. [CrossRef] [PubMed]
140. Martinowich, K.; Hattori, D.; Wu, H.; Fouse, S.; He, F.; Hu, Y.; Fan, G.; Sun, Y.E. DNA methylation-related
chromatin remodeling in activity-dependent BDNF gene regulation. Science 2003, 302, 890–893. [CrossRef]
[PubMed]
141. Varendi, K.; Kumar, A.; Härma, M.A.; Andressoo, J.O. miR-1, miR-10b, miR-155, and miR-191 are novel
regulators of BDNF. Cell. Mol. Life Sci. 2014, 71, 4443–4456. [CrossRef] [PubMed]
142. Boulle, F.; van den Hove, D.L.; Jakob, S.B.; Rutten, B.P.; Hamon, M.; van Os, J.; Lesch, K.P.; Lanfumey, L.;
Steinbusch, H.W.; Kenis, G. Epigenetic regulation of the BDNF gene: Implications for psychiatric disorders.
Mol. Psychiatry 2012, 17, 584–596. [CrossRef] [PubMed]
143. Ikegame, T.; Bundo, M.; Murata, Y.; Kasai, K.; Kato, T.; Iwamoto, K. DNA methylation of the BDNF gene and
its relevance to psychiatric disorders. J. Hum. Genet. 2013, 58, 434–438. [CrossRef] [PubMed]
144. Mitchelmore, C.; Gede, L. Brain derived neurotrophic factor: Epigenetic regulation in psychiatric disorders.
Brain Res. 2014, 1586, 162–172. [CrossRef] [PubMed]
145. Mill, J.; Tang, T.; Kaminsky, Z.; Khare, T.; Yazdanpanah, S.; Bouchard, L.; Jia, P.; Assadzadeh, A.; Flanagan, J.;
Schumacher, A.; et al. Epigenomic profiling reveals DNA-methylation changes associated with major
psychosis. Am. J. Hum. Genet. 2008, 82, 696–711. [CrossRef] [PubMed]
146. Ikegame, T.; Bundo, M.; Sunaga, F.; Asai, T.; Nishimura, F.; Yoshikawa, A.; Kawamura, Y.; Hibino, H.;
Tochigi, M.; Kakiuchi, C.; et al. DNA methylation analysis of BDNF gene promoters in peripheral blood cells
of schizophrenia patients. Neurosci. Res. 2013, 77, 208–214. [CrossRef] [PubMed]
147. Kordi-Tamandani, D.M.; Sahranavard, R.; Torkamanzehi, A. DNA methylation and expression profiles of
the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) genes in patients with
schizophrenia. Mol. Biol. Rep. 2012, 39, 10889–10893. [CrossRef] [PubMed]
148. Melas, P.A.; Rogdaki, M.; Ösby, U.; Schalling, M.; Lavebratt, C.; Ekström, T.J. Epigenetic aberrations in
leukocytes of patients with schizophrenia: Association of global DNA methylation with antipsychotic drug
treatment and disease onset. FASEB J. 2012, 26, 2712–2718. [CrossRef] [PubMed]
149. Guidotti, A.; Dong, E.; Kundakovic, M.; Satta, R.; Grayson, D.R.; Costa, E. Characterization of the action of
antipsychotic subtypes on valproateinduced chromatin remodeling. Trends Pharmacol. Sci. 2009, 30, 55–60.
[CrossRef] [PubMed]
150. Nanko, S.; Hattori, M.; Kuwata, S.; Sasaki, T.; Fukuda, R.; Dai, X.Y.; Yamaguchi, K.; Shibata, Y.;
Kazamatsuri, H. Neurotrophin-3 gene polymorphism associated with schizophrenia. Acta Psychiatr. Scand.
1994, 89, 390–392. [CrossRef] [PubMed]
151. Dawson, E.; Powell, J.F.; Sham, P.C.; Nöthen, M.; Crocq, M.A.; Propping, P.; Körner, J.; Rietschel, M.; van Os, J.;
Wright, P.; et al. An association study of a neurotrophin-3 (NT-3) gene polymorphism with schizophrenia.
Acta Psychiatr. Scand. 1995, 92, 425–428. [CrossRef] [PubMed]
152. Nimganokar, V.l.; Zhang, X.R.; Brar, J.S.; DeLeo, M.; Ganguli, R. Lack of association of schizophrenia with
the neurotrophin-3 gene locus. Acta Psychiatr. Scand. 1995, 92, 464–466. [CrossRef]
153. Jo˘nsson, E.; Brené, S.; Zhang, X.R.; Nimgaonkar, V.L.; Tylec, A.; Schalling, M.; Sedvall, G. Schizophrenia and
neurotrophin-3 alleles. Acta Psychiatr. Scand. 1997, 95, 414–419. [CrossRef] [PubMed]
154. Hattori, M.; Nanko, S. Association of neurotrophin-3 gene variant with severe forms of schizophrenia.
Biochem. Biophys. Res. Commun. 1995, 209, 513–518. [CrossRef] [PubMed]
155. Xiong, P.; Zeng, Y.; Zhu, Z.; Tan, D.; Xu, F.; Lu, J.; Wan, J.; Ma, M. Reduced NGF serum levels and abnormal
P300 event-related potential in first episode schizophrenia. Schizophr. Res. 2010, 119, 34–39. [CrossRef]
[PubMed]
156. Xiong, P.; Zeng, Y.; Wan, J.; Xiaohan, D.H.; Tan, D.; Lu, J.; Xu, F.; Li, H.Y.; Zhu, Z.; Ma, M. The role of NGF
and IL-2 serum level in assisting the diagnosis in first episode schizophrenia. Psychiatry Res. 2011, 189, 72–76.
[CrossRef] [PubMed]
157. Zakharyan, R.; Atshemyan, S.; Gevorgyan, A.; Boyajyan, A. Nerve growth factor and its receptor in
schizophrenia. BBA Clin. 2014, 1, 24–29. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 26 of 38
158. Carlsson, A.; Waters, N.; Carlsson, M.L. Neurotransmitter interactions in schizophrenia-therapeutic
implications. Eur. Arch. Psychiatry Clin. Neurosci. 1999, 249, 37–43. [CrossRef] [PubMed]
159. Howes, O.D.; Kapur, S. The dopamine hypothesis of schizophrenia: Version III—The final common pathway.
Schizophr. Bull. 2009, 35, 549–562. [CrossRef] [PubMed]
160. Kapur, S. Psychosis as a state of aberrant salience: A framework linking biology, phenomenology, and
pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160, 13–23. [CrossRef] [PubMed]
161. Moore, H.; West, A.R.; Grace, A.A. The regulation of forebrain dopamine transmission: Relevance to the
pathophysiology and psychopathology of schizophrenia. Biol. Psychiatry 1999, 46, 40–55. [CrossRef]
162. Seeman, P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987, 1, 133–152.
[CrossRef] [PubMed]
163. Hietala, J.; Syvälahti, E.; Vuorio, K.; Räkköläinen, V.; Bergman, J.; Haaparanta, M.; Solin, O.; Kuoppamäki, M.;
Kirvelä, O.; Ruotsalainen, U.; et al. Presynaptic dopamine function in striatum of neuroleptic-naive
schizophrenic patients. Lancet 1995, 346, 1130–1131. [CrossRef]
164. Laruelle, M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q. J. Nucl. Med.
1998, 42, 211–221. [PubMed]
165. Laruelle, M.; Abi-Dargham, A. Dopamine as the wind of the psychotic fire: New evidence from brain
imaging studies. J. Psychopharmacol. 1999, 13, 358–371. [CrossRef] [PubMed]
166. Laruelle, M.; Abi-Dargham, A.; Gil, R.; Kegeles, L.; Innis, R. Increased dopamine transmission in
schizophrenia: Relationship to illness phases. Biol. Psychiatry 1999, 46, 56–72. [CrossRef]
167. Glenthoj, B.Y.; Mackeprang, T.; Svarer, C.; Rasmussen, H.; Pinborg, L.H.; Friberg, L.; Baaré, W.;
Hemmingsen, R.; Videbaek, C. Frontal dopamine D(2/3) receptor binding in drug-naive first-episode
schizophrenic patients correlates with positive psychotic symptoms and gender. Biol. Psychiatry 2006, 60,
621–629. [CrossRef] [PubMed]
168. Kestler, L.P.; Walker, E.; Vega, E.M. Dopamine receptors in the brains of schizophrenia patients:
A meta-analysis of the findings. Behav. Pharmacol. 2001, 12, 355–371. [CrossRef] [PubMed]
169. Kellendonk, C.; Simpson, E.H.; Polan, H.J.; Malleret, G.; Vronskaya, S.; Winiger, V.; Moore, H.; Kandel, E.R.
Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent
abnormalities in prefrontal cortex functioning. Neuron 2006, 49, 603–615. [CrossRef] [PubMed]
170. Seeman, P.; Niznik, H.B. Dopamine receptors and transporters in Parkinson’s disease and schizophrenia.
FASEB J. 1990, 4, 2737–2744. [PubMed]
171. Creese, I.; Burt, D.R.; Snyder, S.H. Dopamine receptor binding predicts clinical and pharmacological potencies
of antischizophrenic drugs. Science 1976, 192, 481–483. [CrossRef] [PubMed]
172. Howes, O.D.; Egerton, A.; Allan, V.; McGuire, P.; Stokes, P.; Kapur, S. Mechanisms underlying psychosis and
antipsychotic treatment response in schizophrenia: Insights from PET and SPECT imaging. Curr. Pharm. Des.
2009, 15, 2550–2559. [CrossRef] [PubMed]
173. Miyamoto, S.; Duncan, G.E.; Marx, C.E.; Lieberman, J.A. Treatments for schizophrenia: A critical review of
pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10, 79–104. [CrossRef]
[PubMed]
174. Abi-Dargham, A.; Kegeles, L.S.; Zea-Ponce, Y.; Mawlawi, O.; Martinez, D.; Mitropoulou, V.; O’Flynn, K.;
Koenigsberg, H.W.; Van Heertum, R.; Cooper, T.; et al. Striatal amphetamine-induced dopamine release in
patients with schizotypal personality disorder studied with single photon emission computed tomography
and [123I] iodobenzamide. Biol. Psychiatry 2004, 55, 1001–1006. [CrossRef] [PubMed]
175. Laruelle, M.; Abi-Dargham, A.; van Dyck, C.H.; Gil, R.; D’Souza, C.D.; Erdos, J.; McCance, E.;
Rosenblatt, W.; Fingado, C.; Zoghbi, S.S.; et al. Single photon emission computerized tomography imaging
of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA
1996, 93, 9235–9240. [CrossRef] [PubMed]
176. Breier, A.; Su, T.P.; Saunders, R.; Carson, R.E.; Kolachana, B.S.; de Bartolomeis, A.; Weinberger, D.R.;
Weisenfeld, N.; Malhotra, A.K.; Eckelman, W.C.; et al. Schizophrenia is associated with elevated
amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission
tomography method. Proc. Natl. Acad. Sci. USA 1997, 94, 2569–2574. [CrossRef] [PubMed]
177. Abi-Dargham, A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J.
Neuropsychopharmacol. 2004, 7 (Suppl. 1), S1–S5. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 27 of 38
178. Abi-Dargham, A.; Moore, H. Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia.
Neuroscientist 2003, 9, 404–416. [CrossRef] [PubMed]
179. Karlsson, P.; Smith, L.; Farde, L.; Härnryd, C.; Sedvall, G.; Wiesel, F.A. Lack of apparent antipsychotic effect
of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacol. Berl.
1995, 121, 309–316. [CrossRef]
180. Okubo, Y.; Suhara, T.; Sudo, Y.; Toru, M. Possible role of dopamine D1 receptors in schizophrenia.
Mol. Psychiatry 1997, 2, 291–292. [CrossRef] [PubMed]
181. Davis, K.L.; Kahn, R.S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: A review and reconceptualization.
Am. J. Psychiatry 1991, 148, 1474–1486. [PubMed]
182. Meyer-Lindenberg, A.; Miletich, R.S.; Kohn, P.D.; Esposito, G.; Carson, R.E.; Quarantelli, M.; Weinberger, D.R.;
Berman, K.F. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in
schizophrenia. Nat. Neurosci. 2002, 5, 267–271. [CrossRef] [PubMed]
183. Sesack, S.R.; Carr, D.B. Selective prefrontal cortex inputs to dopamine cells: Implications for schizophrenia.
Physiol. Behav. 2002, 77, 513–517. [CrossRef]
184. Stahl, S.M. Describing an atypical antipsychotic: Receptor binding and its role in pathophysiology. Prim. Care
Companion J. Clin. Psychiatry 2003, 5, 9–13.
185. Harrison, P.J.; Owen, M.J. Genes for schizophrenia? Recent findings and their pathophysiological
implications. Lancet 2003, 361, 417–419. [CrossRef]
186. Berry, N.; Jobanputra, V.; Pal, H. Molecular genetics of schizophrenia: A critical review. J. Psychiatry Neurosci.
2003, 28, 415–429. [PubMed]
187. Howes, O.D.; McCutcheon, R.; Owen, M.J.; Murray, R.M. The Role of Genes, Stress, and Dopamine in the
Development of Schizophrenia. Biol. Psychiatry 2017, 81, 9–20. [CrossRef] [PubMed]
188. Ohara, K.; Nakamura, Y.; Xie, D.W.; Ishigaki, T.; Deng, Z.L.; Tani, K.; Zhang, H.Y.; Kondo, N.; Liu, J.C.;
Miyasato, K.; et al. Polymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophrenia.
Biol. Psychiatry 1996, 40, 1209–1217. [CrossRef]
189. Talkowski, M.E.; Bamne, M.; Mansour, H.; Nimgaonkar, V.L. Dopamine genes and schizophrenia: Case
closed or evidence pending? Schizophr. Bull. 2007, 33, 1071–1081. [CrossRef] [PubMed]
190. Ikeda, M.; Yamanouchi, Y.; Kinoshita, Y.; Kitajima, T.; Yoshimura, R.; Hashimoto, S.; O’Donovan, M.C.;
Nakamura, J.; Ozaki, N.; Iwata, N. Variants of dopamine and serotonin candidate genes as predictors of
response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008, 9, 1437–1443.
[CrossRef] [PubMed]
191. Lencz, T.; Robinson, D.G.; Xu, K.; Ekholm, J.; Sevy, S.; Gunduz-Bruce, H.; Woerner, M.G.; Kane, J.M.;
Goldman, D.; Malhotra, A.K. DRD2 promoter region variation as a predictor of sustained response to
antipsychotic medication in first-episode schizophrenia patients. Am. J. Psychiatry 2006, 163, 529–531.
[CrossRef] [PubMed]
192. Reynolds, G.P.; Yao, Z.; Zhang, X.; Sun, J.; Zhang, Z. Pharmacogenetics of treatment in first-episode
schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative
symptom response. Eur. Neuropsychopharmacol. 2005, 15, 143–151. [CrossRef] [PubMed]
193. Zalsman, G.; Frisch, A.; Lev-Ran, S.; Martin, A.; Michaelovsky, E.; Bensason, D.; Gothelf, D.; Nahshoni, E.;
Tyano, S.; Weizman, A. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with
schizophrenia: A pilot pharmacogenetic study. Eur. Neuropsychopharmacol. 2003, 13, 183–185. [CrossRef]
194. Buttarelli, F.R.; Fanciulli, A.; Pellicano, C.; Pontieri, F.E. The dopaminergic system in peripheral blood
lymphocytes: From physiology to pharmacology and potential applications to neuropsychiatric disorders.
Curr. Neuropharmacol. 2011, 9, 278–288. [PubMed]
195. Dean, B.; Kulkarni, J.; Copolov, D.L.; Shrikanthan, P.; Malone, V.; Hill, C. Dopamine uptake by platelets from
subjects with schizophrenia: A correlation with the delusional state of the patient. Psychiatry Res. 1992, 41,
17–24. [CrossRef]
196. Liu, L.; Jia, F.; Yuan, G.; Chen, Z.; Yao, J.; Li, H.; Fang, C. Tyrosine hydroxylase, interleukin-1β and tumor
necrosis factor-α are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as
determined by semi-quantitative analysis. Psychiatry Res. 2010, 176, 1–7. [CrossRef] [PubMed]
197. Liu, L.; Yuan, G.; Cheng, Z.; Zhang, G.; Liu, X.; Zhang, H. Identification of the mRNA expression status of
the dopamine D2 receptor and dopamine transporter in peripheral blood lymphocytes of schizophrenia
patients. PLoS ONE 2013, 8, e75259. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 28 of 38
198. Marazziti, D.; Catena Dell’osso, M.; Baroni, S.; Masala, I.; Dell’Osso, B.; Consoli, G.; Giannaccini, G.; Betti, L.;
Lucacchini, A. Alterations of the dopamine transporter in resting lymphocytes of patients with different
psychotic disorders. Psychiatry Res. 2010, 175, 54–57. [CrossRef] [PubMed]
199. Arrúe, A.; Dávila, R.; Zumárraga, M.; Basterreche, N.; González-Torres, M.A.; Goienetxea, B.; Zamalloa, M.I.;
Anguiano, J.B.; Guimón, J. GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.
Neurochem. Res. 2010, 35, 247–253. [CrossRef] [PubMed]
200. Luykx, J.J.; Bakker, S.C.; Lentjes, E.; Neeleman, M.; Strengman, E.; Mentink, L.; DeYoung, J.; de Jong, S.;
Sul, J.H.; Eskin, E.; et al. Genome-wide association study of monoamine metabolite levels in human
cerebrospinal fluid. Mol. Psychiatry 2014, 19, 228–234. [CrossRef] [PubMed]
201. Siever, L.J.; Amin, F.; Coccaro, E.F.; Bernstein, D.; Kavoussi, R.J.; Kalus, O.; Horvath, T.B.; Warne, P.;
Davidson, M.; Davis, K.L. Plasma homovanillic acid in schizotypal personality disorder. Am. J. Psychiatry
1991, 148, 1246–1248. [PubMed]
202. Sumiyoshi, T.; Kurachi, M.; Kurokawa, K.; Yotsutsuji, T.; Uehara, T.; Itoh, H.; Saitoh, O. Plasma homovanillic
acid in the prodromal phase of schizophrenia. Biol. Psychiatry 2000, 47, 428–433. [CrossRef]
203. Baeza, I.; Castro-Fornieles, J.; Deulofeu, R.; de la Serna, E.; Goti, J.; Salvà, J.; Bernardo, M. Plasma homovanillic
acid differences in clinical subgroups of first episode schizophrenic patients. Psychiatry Res. 2009, 168,
110–118. [CrossRef] [PubMed]
204. Koreen, A.R.; Lieberman, J.; Alvir, J.; Mayerhoff, D.; Loebel, A.; Chakos, M.; Amin, F.; Cooper, T.
Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
Arch. Gen. Psychiatry 1994, 51, 132–138. [CrossRef] [PubMed]
205. Nagaoka, S.; Iwamoto, N.; Arai, H. First-episode neuroleptic free schizophrenics: Concentrations of
monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol
treatment. Biol. Psychiatry 1997, 41, 857–864. [CrossRef]
206. Bondy, B.; Ackenheil, M.; Elbers, R.; Fröhler, M. Binding of 3H-spiperone to human lymphocytes: A biological
marker in schizophrenia? Psychiatry Res. 1985, 15, 41–48. [CrossRef]
207. Zvara, A.; Szekeres, G.; Janka, Z.; Kelemen, J.Z.; Cimmer, C.; Sántha, M.; Puskás, L.G. Over-expression
of dopamine D2 receptor and inwardly rectifying potassium channel genes in drug-naive schizophrenic
peripheral blood lymphocytes as potential diagnostic markers. Dis. Markers 2005, 21, 61–69. [CrossRef]
[PubMed]
208. Boneberg, E.M.; von Seydlitz, E.; Pröpster, K.; Watzl, H.; Rockstroh, B.; Illges, H. D3 dopamine receptor
mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in
CD4+ -T cells. J. Neuroimmunol. 2006, 173, 180–187. [CrossRef] [PubMed]
209. Singh, A.N.; Barlas, C.; Saeedi, H.; Mishra, R.K. Effect of loxapine on peripheral dopamine-like and serotonin
receptors in patients with schizophrenia. J. Psychiatry Neurosci. 2003, 28, 39–47. [PubMed]
210. Ilani, T.; Ben-Shachar, D.; Strous, R.D.; Mazor, M.; Sheinkman, A.; Kotler, M.; Fuchs, S. A peripheral marker
for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad.
Sci. USA 2001, 98, 625–628. [CrossRef] [PubMed]
211. Kwak, Y.T.; Koo, M.S.; Choi, C.H.; Sunwoo, I. Change of dopamine receptor mRNA expression in lymphocyte
of schizophrenic patients. BMC Med. Genet. 2001, 2, 3. [CrossRef]
212. Vogel, M.; Pfeifer, S.; Schaub, R.T.; Grabe, H.J.; Barnow, S.; Freyberger, H.J.; Cascorbi, I. Decreased levels of
dopamine D3 receptor mRNA in schizophrenic and bipolar patients. Neuropsychobiology 2004, 50, 305–310.
[CrossRef] [PubMed]
213. Bondy, B.; Ackenheil, M.; Birzle, W.; Elbers, R.; Frohler, M. Catecholamines and their receptors in blood:
Evidence for alterations in schizophrenia. Biol. Psychiatry 1984, 19, 1377–1393. [PubMed]
214. Grodzicki, J.; Pardo, M.; Schved, G.; Schlosberg, A.; Fuchs, S.; Kanety, H. Differences in [3H]-spiperone
binding to peripheral blood lymphocytes from neuroleptic responsive and nonresponsive schizophrenic
patients. Biol. Psychiatry 1990, 27, 1327–1330. [CrossRef]
215. Egan, M.F.; Goldberg, T.E.; Kolachana, B.S.; Callicott, J.H.; Mazzanti, C.M.; Straub, R.E.; Goldman, D.;
Weinberger, D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for
schizophrenia. Proc. Natl. Acad. Sci. USA 2001, 98, 6917–6922. [CrossRef] [PubMed]
216. Williams, H.J.; Owen, M.J.; O’Donovan, M.C. Is COMT a susceptibility gene for schizophrenia? Schizophr. Bull.
2007, 33, 635–641. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 29 of 38
217. Owen, M.J.; Williams, N.M.; O’Donovan, M.C. The molecular genetics of schizophrenia: New findings
promise new insights. Mol. Psychiatry 2004, 9, 14–27. [CrossRef] [PubMed]
218. Williams, N.M.; Owen, M.J. Genetic abnormalities of chromosome 22 and the development of psychosis.
Curr. Psychiatry Rep. 2004, 6, 176–182. [CrossRef] [PubMed]
219. Lachman, H.M.; Papolos, D.F.; Saito, T.; Yu, Y.M.; Szumlanski, C.L.; Weinshilboum, R.M. Human
catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential
application to neuropsychiatric disorders. Pharmacogenetics 1996, 6, 243–250. [CrossRef] [PubMed]
220. Tunbridge, E.M.; Harrison, P.J.; Weinberger, D.R. Catechol-omethyltransferase, cognition, and psychosis:
Val158Met and beyond. Biol. Psychiatry 2006, 60, 141–151. [CrossRef] [PubMed]
221. Da Silva Alves, F.; Figee, M.; van Amelsvoort, T.; Veltman, D.; de Haan, L. The revised dopamine hypothesis
of schizophrenia: Evidence from pharmacological MRI studies with atypical antipsychotic medication.
Psychopharmacol. Bull. 2008, 41, 121–132. [PubMed]
222. Ohmori, O.; Shinkai, T.; Kojima, H.; Terao, T.; Suzuki, T.; Mita, T.; Abe, K. Association study of a functional
catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics. Neurosci. Lett. 1998, 243,
109–112. [CrossRef]
223. Glatt, S.J.; Faraone, S.V.; Tsuang, M.T. Association between a functional catechol O-methyltransferase gene
polymorphism and schizophrenia: Meta-analysis of case-control and family-based studies. Am. J. Psychiatry
2003, 160, 469–476. [CrossRef] [PubMed]
224. Li, T.; Sham, P.C.; Vallada, H.; Xie, T.; Tang, X.; Murray, R.M.; Liu, X.; Collier, D.A. Preferential transmission
of the high activity allele of COMT in schizophrenia. Psychiatr. Genet. 1996, 6, 131–133. [CrossRef] [PubMed]
225. Shifman, S.; Bronstein, M.; Sternfeld, M.; Pisanté-Shalom, A.; Lev-Lehman, E.; Weizman, A.; Reznik, I.;
Spivak, B.; Grisaru, N.; Karp, L.; et al. A highly significant association between a COMT haplotype and
schizophrenia. Am. J. Hum. Genet. 2002, 71, 1296–1302. [CrossRef] [PubMed]
226. Strous, R.D.; Bark, N.; Parsia, S.S.; Volavka, J.; Lachman, H.M. Analysis of a functional catechol-O-
methyltransferase gene polymorphism in schizophrenia: Evidence for association with aggressive and
antisocial behavior. Psychiatry Res. 1997, 69, 71–77. [CrossRef]
227. Nunokawa, A.; Watanabe, Y.; Muratake, T.; Kaneko, N.; Koizumi, M.; Someya, T. No associations exist
between five functional polymorphisms in the catechol-O-methyltransferase gene and schizophrenia in
a Japanese population. Neurosci. Res. 2007, 58, 291–296. [CrossRef] [PubMed]
228. Semwal, P.; Prasad, S.; Varma, P.G.; Bhagwat, A.M.; Deshpande, S.N.; Thelma, B.K. Candidate gene
polymorphisms among North Indians and their association with schizophrenia in a case-control study.
J. Genet. 2002, 81, 65–71. [CrossRef] [PubMed]
229. Fan, J.B.; Zhang, C.S.; Gu, N.F.; Li, X.W.; Sun, W.W.; Wang, H.Y.; Feng, G.Y.; St Clair, D.; He, L.
Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia:
A large-scale association study plus meta-analysis. Biol. Psychiatry 2005, 57, 139–144. [CrossRef] [PubMed]
230. Lee, S.G.; Joo, Y.; Kim, B.; Chung, S.; Kim, H.L.; Lee, I.; Choi, B.; Kim, C.; Song, K. Association of Ala72Ser
polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum. Genet. 2005, 116,
319–328. [CrossRef] [PubMed]
231. Allen, N.C.; Bagade, S.; McQueen, M.B.; Ioannidis, J.P.; Kavvoura, F.K.; Khoury, M.J.; Tanzi, R.E.; Bertram, L.
Systematic meta analyses and field synopsis of genetic association studies in schizophrenia: The SzGene
database. Nat. Genet. 2008, 40, 827–834. [CrossRef] [PubMed]
232. Chien, Y.L.; Liu, C.M.; Fann, C.S.; Liu, Y.L.; Hwu, H.G. Association of the 3′ region of COMT with
schizophrenia in Taiwan. J. Formos. Med. Assoc. 2009, 108, 301–309. [CrossRef]
233. Gupta, M.; Bhatnagar, P.; Grover, S.; Kaur, H.; Baghel, R.; Bhasin, Y.; Chauhan, C.; Verma, B.; Manduva, V.;
Mukherjee, O.; et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia
and response to antipsychotic treatment. Pharmacogenomics 2009, 10, 385–397. [CrossRef] [PubMed]
234. Pal, P.; Mihanovic, M.; Molnar, S.; Xi, H.; Sun, G.; Guha, S.; Jeran, N.; Tomljenovic´, A.; Malnar, A.; Missoni, S.;
et al. Association of tagging single nucleotide polymorphisms on 8 candidate genes in dopaminergic
pathway with schizophrenia in Croatian population. Croat. Med. J. 2009, 50, 361–369. [CrossRef] [PubMed]
235. Prata, D.P.; Mechelli, A.; Fu, C.H.; Picchioni, M.; Toulopoulou, T.; Bramon, E.; Walshe, M.; Murray, R.M.;
Collier, D.A.; McGuire, P. Epistasis between the DAT 3′ UTR VNTR and the COMT Val158Met SNP on
cortical function in healthy subjects and patients with schizophrenia. Proc. Natl. Acad. Sci. USA 2009, 106,
13600–13605. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 30 of 38
236. Tan, H.Y.; Chen, Q.; Sust, S.; Buckholtz, J.W.; Meyers, J.D.; Egan, M.F.; Mattay, V.S.; Meyer-Lindenberg, A.;
Weinberger, D.R.; Callicott, J.H. Epistasis between catechol-O-methyltransferase and type II metabotropic
glutamate receptor 3 genes on working memory brain function. Proc. Natl. Acad. Sci. USA 2007, 104,
12536–12541. [CrossRef] [PubMed]
237. Abdolmaleky, H.M.; Cheng, K.H.; Faraone, S.V.; Wilcox, M.; Glatt, S.J.; Gao, F.; Smith, C.L.; Shafa, R.; Aeali, B.;
Carnevale, J.; et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and
bipolar disorder. Hum. Mol. Genet. 2006, 15, 3132–3145. [CrossRef] [PubMed]
238. Nishioka, M.; Bundo, M.; Koike, S.; Takizawa, R.; Kakiuchi, C.; Araki, T.; Kasai, K.; Iwamoto, K.
Comprehensive DNA methylation analysis of peripheral blood cells derived from patients with first-episode
schizophrenia. J. Hum. Genet. 2013, 58, 91–97. [CrossRef] [PubMed]
239. Nohesara, S.; Ghadirivasfi, M.; Mostafavi, S.; Eskandari, M.R.; Ahmadkhaniha, H.; Thiagalingam, S.;
Abdolmaleky, H.M. DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in
schizophrenia and bipolar disorder. J. Psychiatr. Res. 2011, 45, 1432–1438. [CrossRef] [PubMed]
240. Dingemanse, J.; Jorga, K.M.; Schmitt, M.; Gieschke, R.; Fotteler, B.; Zürcher, G.; Da Prada, M.; van Brummelen, P.
Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor
tolcapone during first administration to humans. Clin. Pharmacol. Ther. 1995, 57, 508–517. [CrossRef]
241. Ferreira, J.J.; Almeida, L.; Cunha, L.; Ticmeanu, M.; Rosa, M.M.; Januário, C.; Mitu, C.E.; Coelho, M.;
Correia-Guedes, L.; Morgadinho, A.; et al. Effects of nebicapone on levodopa pharmacokinetics,
catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Clin. Neuropharmacol. 2008, 31, 2–18. [CrossRef] [PubMed]
242. Forsberg, M.; Lehtonen, M.; Heikkinen, M.; Savolainen, J.; Jarvinen, T.; Mannisto, P.T. Pharmacokinetics and
pharmacodynamics of entacapone and tolcapone after acute and repeated administration: A comparative
study in the rat. J. Pharmacol. Exp. Ther. 2003, 304, 498–506. [CrossRef] [PubMed]
243. Kiss, L.E.; Ferreira, H.S.; Torrão, L.; Bonifácio, M.J.; Palma, P.N.; Soares-da-Silva, P.; Learmonth, D.A.
Discovery of a long acting, peripherally selective inhibitor of catechol-O-methyltransferase. J. Med. Chem.
2010, 53, 3396–3411. [CrossRef] [PubMed]
244. Mannisto, P.T.; Kaakkola, S. Catechol-Omethyltransferase [COMT]: Biochemistry, molecular biology,
pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51, 593–628.
[PubMed]
245. Onofrj, M.; Thomas, A.; Iacono, D.; Di Iorio, A.; Bonanni, L. Switch over from tolcapone to entacapone in
severe Parkinson’s disease patients. Eur. Neurol. 2001, 46, 11–16. [CrossRef] [PubMed]
246. Zürcher, G.; Colzi, A.; Da Prada, M. Ro 40-7592: Inhibition of COMT in rat brain and extracerebral tissues.
J. Neural Transm. Suppl. 1990, 32, 375–380. [PubMed]
247. Tunbridge, E.M.; Bannerman, D.M.; Sharp, T.; Harrison, P.J. Catechol-O-methyltransferase inhibition
improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex.
J. Neurosci. 2004, 24, 5331–5335. [CrossRef] [PubMed]
248. Illi, A.; Kampman, O.; Hänninen, K.; Anttila, S.; Mattila, K.M.; Katila, H.; Rontu, R.; Hurme, M.;
Lehtimäki, T.; Leinonen, E. Catechol-O-methyltransferase val108/158met genotype and response to
antipsychotic medication in schizophrenia. Hum. Psychopharmacol. 2007, 22, 211–215. [CrossRef] [PubMed]
249. Bertolino, A.; Caforio, G.; Blasi, G.; Rampino, A.; Nardini, M.; Weinberger, D.R.; Dallapiccola, B.; Sinibaldi, L.;
Douzgou, S. COMT Val158Met polymorphism predicts negative symptoms response to treatment with
olanzapine in schizophrenia. Schizophr. Res. 2007, 95, 253–255. [CrossRef] [PubMed]
250. Kang, C.Y.; Xu, X.F.; Shi, Z.Y.; Yang, J.Z.; Liu, H.; Xu, H.H. Interaction of catechol-O-methyltransferase
(COMT) Val108/158 Met genotype and risperidone treatment in Chinese Han patients with schizophrenia.
Psychiatry Res. 2010, 176, 94–95. [CrossRef] [PubMed]
251. Molero, P.; Ortuno, F.; Zalacain, M.; Patino-Garcia, A. Clinical involvement of catechol-O-methyltransferase
polymorphisms in schizophrenia spectrum disorders: Influence on the severity of psychotic symptoms and
on the response to neuroleptic treatment. Pharmacogenom. J. 2007, 7, 418–426. [CrossRef] [PubMed]
252. Weickert, T.W.; Goldberg, T.E.; Mishara, A.; Apud, J.A.; Kolachana, B.S.; Egan, M.F.; Weinberger, D.R.
Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic
medications. Biol. Psychiatry 2004, 56, 677–682. [CrossRef] [PubMed]
253. Woodward, N.D.; Jayathilake, K.; Meltzer, H.Y. COMT val108/158met genotype, cognitive function, and
cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 2007, 90, 86–96. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 31 of 38
254. Nolan, K.A.; Czobor, P.; Citrome, L.L.; Krakowski, M.; Lachman, H.M.; Kennedy, J.L.; Ni, X.; Lieberman, J.;
Chakos, M.; Volavka, J. Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and
treatment response to typical and atypical neuroleptics. J. Clin. Psychopharmacol. 2006, 26, 338–340. [CrossRef]
[PubMed]
255. Pelayo-Terán, J.M.; Pérez-Iglesias, R.; Vázquez-Bourgon, J.; Mata, I.; Carrasco-Marín, E.; Vázquez-Barquero, J.L.;
Crespo-Facorro, B. Catechol-O-methyltransferase Val158Met polymorphism and negative symptoms after acute
antipsychotic treatment in first-episode non-affective psychosis. Psychiatry Res. 2011, 185, 286–289. [CrossRef]
[PubMed]
256. Yamanouchi, Y.; Iwata, N.; Suzuki, T.; Kitajima, T.; Ikeda, M.; Ozaki, N. Effect of DRD2, 5-HT2A, and COMT
genes on antipsychotic response to risperidone. Pharmacogenom. J. 2003, 3, 356–361. [CrossRef] [PubMed]
257. Hagen, K.; Stovner, L.J.; Skorpen, F.; Pettersen, E.; Zwart, J.A. COMT genotypes and use of antipsychotic
medication: Linking population-based prescription database to the HUNT study. Pharmacoepidemiol. Drug Saf.
2008, 17, 372–377. [CrossRef] [PubMed]
258. Inada, T.; Nakamura, A.; Iijima, Y. Relationship between catechol-O-methyltransferase polymorphism and
treatment resistant schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 120, 35–39. [CrossRef]
[PubMed]
259. Fijal, B.A.; Kinon, B.J.; Kapur, S.; Stauffer, V.L.; Conley, R.R.; Jamal, H.H.; Kane, J.M.; Witte, M.M.; Houston, J.P.
Candidate-gene association analysis of response to risperidone in African-American and white patients with
schizophrenia. Pharmacogenom. J. 2009, 9, 311–318. [CrossRef] [PubMed]
260. Abi-Dargham, A. Alterations of serotonin transmission in schizophrenia. Int. Rev. Neurobiol. 2007, 78,
133–164. [PubMed]
261. Meltzer, H.Y.; Li, Z.; Kaneda, Y.; Ichikawa, J. Serotonin receptors: Their key role in drugs to treat
schizophrenia. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2003, 27, 1159–1172. [CrossRef] [PubMed]
262. Kapur, S.; Remington, G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry
1996, 153, 466–476. [PubMed]
263. Stephan, K.E.; Friston, K.J.; Frith, C.D. Dysconnection in schizophrenia: From abnormal synaptic plasticity
to failures of self-monitoring. Schizophr. Bull. 2009, 35, 509–527. [CrossRef] [PubMed]
264. Dean, B. A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in
schizophrenia. Clin. Exp. Pharmacol. Physiol. 2001, 28, 74–78. [CrossRef] [PubMed]
265. Boyer, P.; Phillips, J.L.; Rousseau, F.L.; Ilivitsky, S. Hippocampal abnormalities and memory deficits:
New evidence of a strong pathophysiological link in schizophrenia. Brain Res. Rev. 2007, 54, 92–112.
[CrossRef] [PubMed]
266. Puig, M.; Gener, T. Serotonin modulation of prefronto-hippocampal rhythms in health and disease.
ACS Chem. Neurosci. 2015, 6, 1017–1025. [CrossRef] [PubMed]
267. Svob Strac, D.; Pivac, N.; Mück-Seler, D. The serotonergic system and cognitive function. Transl. Neurosci.
2016, 7, 35–49. [CrossRef] [PubMed]
268. Joyce, J.N.; Shane, A.; Lexow, N.; Winokur, A.; Casanova, M.F.; Kleinman, J.E. Serotonin uptake sites and
serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993, 8,
315–336. [CrossRef] [PubMed]
269. Laruelle, M.; Abi-Dargham, A.; Casanova, M.F.; Toti, R.; Weinberger, D.R.; Kleinman, J.E. Selective abnormalities
of prefrontal serotonergic receptors in schizophrenia: A postmortem study. Arch. Gen. Psychiatry 1993, 50, 810–818.
[CrossRef] [PubMed]
270. Selvaraj, S.; Arnone, D.; Cappai, A.; Howes, O. Alterations in the serotonin system in schizophrenia:
A systematic review and metaanalysis of postmortem and molecular imaging studies. Neurosci. Biobehav. Rev.
2014, 45, 233–245. [CrossRef] [PubMed]
271. Ichikawa, J.; Ishii, H.; Bonaccorso, S.; Fowler, W.L.; O’Laughlin, I.A.; Meltzer, H.Y. 5-HT2A and D2 receptor
blockade increases cortical DA release via 5-HT1A receptor activation: A possible mechanism of atypical
antipsychotic-induced cortical dopamine release. J. Neurochem. 2001, 76, 1521–1531. [CrossRef] [PubMed]
272. López-Figueroa, A.L.; Norton, C.S.; López-Figueroa, M.O.; Armellini-Dodel, D.; Burke, S.; Akil, H.; López, J.F.;
Watson, S.J. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major
depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 2004, 55, 225–233. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 32 of 38
273. Okubo, Y.; Suhara, T.; Suzuki, K.; Kobayashi, K.; Inoue, O.; Terasaki, O.; Someya, Y.; Sassa, T.; Sudo, Y.;
Matsushima, E.; et al. Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission
tomography. Life Sci. 2000, 66, 2455–2464. [CrossRef]
274. Rasmussen, H.; Erritzoe, D.; Andersen, R.; Ebdrup, B.H.; Aggernaes, B.; Oranje, B.; Kalbitzer, J.; Madsen, J.;
Pinborg, L.H.; Baaré, W.; et al. Decreased frontal serotonin 2A receptor binding in antipsychotic-naive
patients with first-episode schizophrenia. Arch. Gen. Psychiatry 2010, 67, 9–16. [CrossRef] [PubMed]
275. Abi-Dargham, A.; Laruelle, M.; Lipska, B.; Jaskiw, G.E.; Wong, D.T.; Robertson, D.W.; Weinberger, D.R.;
Kleinman, J.E. Serotonin 5-HT3 receptors in schizophrenia: A postmortem study of the amygdala. Brain Res.
1993, 616, 53–57. [CrossRef]
276. Dean, B.; Tomaskovic-Crook, E.; Opeskin, K.; Keks, N.; Copolov, D. No change in the density of the
serotonin1A receptor, the serotonin 4 receptor or the serotonin transporter in the dorsolateral prefrontal
cortex from subjects with schizophrenia. Neurochem. Int. 1999, 34, 109–115. [CrossRef]
277. Lennertz, L.; Wagner, M.; Frommann, I.; Schulze-Rauschenbach, S.; Schuhmacher, A.; Kühn, K.U.; Pukrop, R.;
Klosterkötter, J.; Wölwer, W.; Gaebel, W.; et al. A coding variant of the novel serotonin receptor subunit
5-HT3E influences sustained attention in schizophrenia patients. Eur. Neuropsychopharmacol. 2010, 20,
414–420. [CrossRef] [PubMed]
278. Suzuki, T.; Iwata, N.; Kitamura, Y.; Kitajima, T.; Yamanouchi, Y.; Ikeda, M.; Nishiyama, T.; Kamatani, N.;
Ozaki, N. Association of a haplotype in the serotonin 5-HT4 receptor gene (HTR4) with Japanese
schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 121B, 7–13. [CrossRef] [PubMed]
279. Dean, B.; Pavey, G.; Thomas, D.; Scarr, E. Cortical serotonin7, 1D and 1F receptors: Effects of schizophrenia,
suicide and antipsychotic drug treatment. Schizophr. Res. 2006, 88, 265–274. [CrossRef] [PubMed]
280. East, S.Z.; Burnet, P.W.; Kerwin, R.W.; Harrison, P.J. An RT-PCR study of 5-HT6 and 5-HT7 receptor mRNAs
in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophr. Res. 2002, 57, 15–26.
[CrossRef]
281. Ikeda, M.; Iwata, N.; Kitajima, T.; Suzuki, T.; Yamanouchi, Y.; Kinoshita, Y.; Ozaki, N. Positive association of
the serotonin 5-HT7 receptor gene with schizophrenia in a Japanese population. Neuropsychopharmacology
2006, 31, 866–871. [CrossRef] [PubMed]
282. Roth, B.L.; Craigo, S.C.; Choudhary, M.S.; Uluer, A.; Monsma, F.J., Jr.; Shen, Y.; Meltzer, H.Y.; Sibley, D.R.
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7
receptors. J. Pharmacol. Exp. Ther. 1994, 268, 1403–1410.
283. Ertugrul, A.; Ucar, G.; Basar, K.; Demir, B.; Yabanoglu, S.; Ulug, B. Influence of clozapine on platelet serotonin,
Monoamino oxidase and plasma serotonin levels. Psychiatry Res. 2007, 149, 49–57. [CrossRef] [PubMed]
284. Muck-Seler, D.; Pivac, N.; Jakovljevic, M. Sex differences, season of birth and platelet 5-HT levels in
schizophrenic patients. J. Neural Transm. 1999, 106, 337–347. [PubMed]
285. Muck-Seler, D.; Pivac, N.; Mustapic, M.; Crncevic, Z.; Jakovljevic, M.; Sagud, M. Platelet serotonin and
plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res. 2004, 127,
217–226. [CrossRef] [PubMed]
286. Van der Heijden, F.M.; Tuinier, S.; Fekkes, D.; Sijben, A.E.; Kahn, R.S.; Verhoeven, W.M. Atypical
antipsychotics and the relevance of glutamate and serotonin. Eur. Neuropsychopharmacol. 2004, 14, 259–265.
[CrossRef] [PubMed]
287. Kaneda, Y.; Fujii, A.; Nagamine, I. Platelet serotonin concentrations in medicated schizophrenic patients.
Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25, 983–992. [CrossRef]
288. Arranz, M.J.; de Leon, J. Pharmacogenetics and pharmacogenomics of schizophrenia: A review of last decade
of research. Mol. Psychiatry 2007, 12, 707–747. [CrossRef] [PubMed]
289. Baou, M.; Boumba, V.A.; Petrikis, P.; Rallis, G.; Vougiouklakis, T.; Mavreas, V. A review of genetic alterations
in the serotonin pathway and their correlation with psychotic diseases and response to atypical antipsychotics.
Schizophr. Res. 2016, 170, 18–29. [CrossRef] [PubMed]
290. Zhang, J.-P.; Malhotra, A.K. Pharmacogenetics and Antipsychotics: Therapeutic Efficacy and Side Effects
Prediction. Expert Opin. Drug Metab. Toxicol. 2011, 7, 9–37. [CrossRef] [PubMed]
291. Abdolmaleky, H.M.; Faraone, S.V.; Glatt, S.J.; Tsuang, M.T. Meta-analysis of association between the T102C
polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr. Res. 2004, 67, 53–62. [CrossRef]
Int. J. Mol. Sci. 2017, 18, 733 33 of 38
292. Williams, J.; Spurlock, G.; McGuffin, P.; Mallet, J.; Nöthen, M.M.; Gill, M.; Aschauer, H.; Nylander, P.O.;
Macciardi, F.; Owen, M.J. Association between schizophrenia and T102C polymorphism of the
5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia
(EMASS) Group. Lancet 1996, 347, 1294–1296. [CrossRef]
293. Vázquez-Bourgon, J.; Arranz, M.J.; Mata, I.; Pelayo-Terán, J.M.; Pérez-Iglesias, R.; Medina-González, L.;
Carrasco-Marín, E.; Vázquez-Barquero, J.L.; Crespo-Facorro, B. Serotonin transporter polymorphisms and
early response to antipsychotic treatment in first episode of psychosis. Psychiatry Res. 2010, 175, 189–194.
[CrossRef] [PubMed]
294. Reynolds, G.P. Weight gain, antipsychotic drug treatment and pharmacogenomics. Pharmacogenomics 2002, 3,
567–570. [CrossRef] [PubMed]
295. Reynolds, G.P.; Zhang, Z.; Zhang, X. Polymorphism of the promoter region of the serotonin 5-HT(2C)
receptor gene and clozapine-induced weight gain. Am. J. Psychiatry 2003, 160, 677–679. [CrossRef] [PubMed]
296. Templeman, L.A.; Reynolds, G.P.; Arranz, B.; San, L. Polymorphisms of the 5-HT2C receptor and leptin
genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode
psychosis. Pharmacogenet. Genom. 2005, 15, 195–200. [CrossRef]
297. Zhang, J.P.; Lencz, T.; Zhang, R.X.; Nitta, M.; Maayan, L.; John, M.; Robinson, D.G.; Fleischhacker, W.W.;
Kahn, R.S.; Ophoff, R.A.; et al. Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain:
A Systematic Review and Meta-analysis. Schizophr. Bull. 2016, 42, 1418–1437. [CrossRef] [PubMed]
298. Güzey, C.; Scordo, M.G.; Spina, E.; Landsem, V.M.; Spigset, O. Antipsychotic-induced extrapyramidal
symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and
transporter polymorphisms. Eur. J. Clin. Pharmacol. 2007, 63, 233–241. [CrossRef] [PubMed]
299. Al Hadithy, A.F.; Ivanova, S.A.; Pechlivanoglou, P.; Semke, A.; Fedorenko, O.; Kornetova, E.; Ryadovaya, L.;
Brouwers, J.R.; Wilffert, B.; Bruggeman, R.; et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene
polymorphisms in Russian psychiatric inpatients from Siberia. Prog. Neuropsychopharmacol. Biol. Psychiatry
2009, 33, 475–481. [CrossRef] [PubMed]
300. Knol, W.; van Marum, R.J.; Jansen, P.A.; Strengman, E.; Al Hadithy, A.F.; Wilffert, B.; Schobben, A.F.;
Ophoff, R.A.; Egberts, T.C. Genetic variation and the risk of haloperidol-related parkinsonism in elderly
patients: A candidate gene approach. J. Clin. Psychopharmacol. 2013, 33, 405–410. [CrossRef] [PubMed]
301. Ghadirivasfi, M.; Nohesara, S.; Ahmadkhaniha, H.R.; Eskandari, M.B.; Mostafavi, S.; Thiagalingam, S.
Hypomethylation of the serotonin receptor type 2A gene (HTR2A) at T102C plymorphic site in DNA derived
from the sliva of patients with schizophrenia and bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet.
2011, 156, 536–545. [CrossRef] [PubMed]
302. Dunlop, J.; Marquis, K.L.; Lim, H.K.; Leung, L.; Kao, J.; Cheesman, C.; Rosenzweig-Lipson, S.
Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple
indications. CNS Drug Rev. 2006, 12, 167–177. [CrossRef] [PubMed]
303. Siuciak, J.A.; Chapin, D.S.; McCarthy, S.A.; Guanowsky, V.; Brown, J.; Chiang, P.; Marala, R.; Patterson, T.;
Seymour, P.A.; Swick, A.; et al. CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of
antipsychotic activity. Neuropharmacology 2007, 52, 279–290. [CrossRef] [PubMed]
304. Zhang, Z.J.; Kang, W.H.; Li, Q.; Wang, X.Y.; Yao, S.M.; Ma, A.Q. Beneficial effects of ondansetron as
an adjunct to haloperidol for chronic, treatment resistant schizophrenia: A double-blind, randomized,
placebo-controlled study. Schizophr. Res. 2006, 88, 102–110. [CrossRef] [PubMed]
305. Mitchell, E.S.; Neumaier, J.F. 5-HT6 receptors: A novel target for cognitive enhancement. Pharmacol. Ther.
2005, 108, 320–333. [CrossRef] [PubMed]
306. Fitzgerald, P.J. Is elevated norepinephrine an etiological factor in some cases of schizophrenia? Psychiatry Res.
2014, 30, 497–504. [CrossRef] [PubMed]
307. Kemali, D.; Maj, M.; Galderisi, S.; Grazia Ariano, M.; Starace, F. Factors associated with increased noradrenaline
levels in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990, 14, 49–59. [CrossRef]
308. Lechin, F.; van der Dijs, B. Noradrenergic hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol.
Psychiatry 2005, 29, 777–778. [CrossRef] [PubMed]
309. Yamamoto, K.; Ozawa, N.; Shinba, T.; Hoshino, T.; Yoshii, M. Possible noradrenergic dysfunction in
schizophrenia. Brain Res. Bull. 1994, 35, 529–543. [CrossRef]
310. Yamamoto, K.; Hornykiewicz, O. Proposal for a noradrenaline hypothesis of schizophrenia.
Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28, 913–922. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 34 of 38
311. Gattaz, W.F.; Waldmeier, P.; Beckmann, H. CSF monoamine metabolites in schizophrenic patients.
Acta Psychiatr. Scand. 1982, 66, 350–360. [CrossRef] [PubMed]
312. Chang, W.H.; Chen, T.Y.; Lin, S.K.; Lung, F.W.; Lin, W.L.; Hu, W.H.; Yeh, E.K. Plasma catecholamine
metabolites in schizophrenics: Evidence for the two-subtype concept. Biol. Psychiatry 1990, 27, 510–518.
[CrossRef]
313. Kaneko, M.; Honda, K.; Kanno, T.; Horikoshi, R.; Manome, T.; Watanabe, A.; Kumashiro, H. Plasma free
3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment. Neuropsychobiology
1992, 25, 126–129. [CrossRef] [PubMed]
314. Elman, I.; Goldstein, D.S.; Green, A.I.; Eisenhofer, G.; Folio, C.J.; Holmes, C.S.; Pickar, D.; Breier, A. Effects
of risperidone on the peripheral noradrenegic system in patients with schizophrenia: A comparison with
clozapine and placebo. Neuropsychopharmacology 2002, 27, 293–300. [CrossRef]
315. Friedman, J.I.; Adler, D.N.; Davis, K.L. The role of norepinephrine in the pathophysiology of cognitive
disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer’s
disease. Biol. Psychiatry 1999, 46, 1243–1252. [CrossRef]
316. Wallace, T.L.; Bertrand, D. Neuronal α7 Nicotinic Receptors as a Target for the Treatment of Schizophrenia.
Int. Rev. Neurobiol. 2015, 124, 79–111. [PubMed]
317. Tani, M.; Akashi, N.; Hori, K.; Konishi, K.; Kitajima, Y.; Tomioka, H.; Inamoto, A.; Hirata, A.; Tomita, A.;
Koganemaru, T.; et al. Anticholinergic Activity and Schizophrenia. Neurodegener. Dis. 2015, 15, 168–174.
[CrossRef] [PubMed]
318. Mexal, S.; Berger, R.; Logel, J.; Ross, R.G.; Freedman, R.; Leonard, S. Differential regulation of α7 nicotinic
receptor gene (CHRNA7) expression in schizophrenic smokers. J. Mol. Neurosci. 2010, 40, 185–195. [CrossRef]
[PubMed]
319. Perl, O.; Ilani, T.; Strous, R.D.; Lapidus, R.; Fuchs, S. The α7 nicotinic acetylcholine receptor in schizophrenia:
Decreased mRNA levels in peripheral blood lymphocytes. FASEB J. 2003, 17, 1948–1950. [PubMed]
320. Freedman, R.; Hall, M.; Adler, L.E.; Leonard, S. Evidence in postmortem brain tissue for decreased numbers
of hippocampal nicotinic receptors in schizophrenia. Biol. Psychiatry 1995, 38, 22–33. [CrossRef]
321. Court, J.; Spurden, D.; Lloyd, S.; McKeith, I.; Ballard, C.; Cairns, N.; Kerwin, R.; Perry, R.; Perry, E. Neuronal
nicotinic receptors in dementia with Lewy bodies and schizophrenia: Alpha-bungarotoxin and nicotine
binding in the thalamus. J. Neurochem. 1999, 73, 1590–1597. [CrossRef] [PubMed]
322. Guan, Z.Z.; Zhang, X.; Blennow, K.; Nordberg, A. Decreased protein level of nicotinic receptor α7 subunit in
the frontal cortex from schizophrenic brain. Neuroreport 1999, 10, 1779–1782. [CrossRef] [PubMed]
323. Freedman, R.; Olincy, A.; Ross, R.G.; Waldo, M.C.; Stevens, K.E.; Adler, L.E.; Leonard, S. The genetics of
sensory gating deficits in schizophrenia. Curr. Psychiatry Rep. 2003, 5, 155–161. [CrossRef] [PubMed]
324. Thomsen, M.S.; Christensen, D.Z.; Hansen, H.H.; Redrobe, J.P.; Mikkelsen, J.D. α(7) Nicotinic acetylcholine
receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment.
Neuropharmacology 2009, 56, 1001–1009. [CrossRef] [PubMed]
325. Thomsen, M.S.; Hansen, H.H.; Timmerman, D.B.; Mikkelsen, J.D. Cognitive improvement by activation of
α7 nicotinic acetylcholine receptors: From animal models to human pathophysiology. Curr. Pharm. Des.
2010, 16, 323–343. [CrossRef] [PubMed]
326. Carruthers, S.P.; Gurvich, C.T.; Rossell, S.L. The muscarinic system, cognition and schizophrenia.
Neurosci. Biobehav. Rev. 2015, 55, 393–402. [CrossRef] [PubMed]
327. Crook, J.M.; Tomaskovic-Crook, E.; Copolov, D.L.; Dean, B. Decreased muscarinic receptor binding in
subjects with schizophrenia: A study of the human hippocampal formation. Biol. Psychiatry 2000, 48,
381–388. [CrossRef]
328. Mancama, D.; Arranz, M.J.; Landau, S.; Kerwin, R. Reduced expression of the muscarinic 1 receptor cortical
subtype in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 119, 2–6. [CrossRef] [PubMed]
329. Melancon, B.J.; Tarr, J.C.; Panarese, J.D.; Wood, M.R.; Lindsley, C.W. Allosteric modulation of the M1
muscarinic acetylcholine receptor: Improving cognition and a potential treatment for schizophrenia and
Alzheimer’s disease. Drug Discov. Today 2013, 18, 1185–1199. [CrossRef] [PubMed]
330. Cherlyn, S.Y.; Woon, P.S.; Liu, J.J.; Ong, W.Y.; Tsai, G.C.; Sim, K. Genetic association studies of glutamate,
GABA and related genes in schizophrenia and bipolar disorder: A decade of advance. Neurosci. Biobehav. Rev.
2010, 34, 958–977. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 35 of 38
331. Harrison, P.J.; West, V.A. Six degrees of separation: On the prior probability that schizophrenia susceptibility
genes converge on synapses, glutamate and NMDA receptors. Mol. Psychiatry 2006, 11, 981–983. [CrossRef]
[PubMed]
332. Neeman, G.; Blanaru, M.; Bloch, B.; Kremer, I.; Ermilov, M.; Javitt, D.C.; Heresco-Levy, U. Relation of plasma
glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry
2005, 162, 1738–1740. [CrossRef] [PubMed]
333. Nilsson, L.K.; Linderholm, K.R.; Engberg, G.; Paulson, L.; Blennow, K.; Lindström, L.H.; Nordin, C.;
Karanti, A.; Persson, P.; Erhardt, S. Elevated levels of kynurenic acid in the cerebrospinal fluid of male
patients with schizophrenia. Schizophr. Res. 2005, 80, 315–322. [CrossRef] [PubMed]
334. Steullet, P.; Neijt, H.C.; Cuenod, M.; Do, K.Q. Synaptic plasticity impairment and hypofunction of NMDA
receptors induced by glutathione deficit: Relevance to schizophrenia. Neuroscience 2006, 137, 807–819.
[CrossRef] [PubMed]
335. Egerton, A.; Reid, L.; McGregor, S.; Cochran, S.M.; Morris, B.J.; Pratt, J.A. Subchronic and chronic PCP
treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.
Psychopharmacol. Berl. 2008, 198, 37–49. [CrossRef] [PubMed]
336. Javitt, D.C.; Zukin, S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991,
148, 1301–1308. [PubMed]
337. Malhotra, A.K.; Pinals, D.A.; Weingartner, H.; Sirocco, K.; Missar, C.D.; Pickar, D.; Breier, A. NMDA receptor
function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 1996,
14, 301–307. [CrossRef]
338. Kegeles, L.S.; Abi-Dargham, A.; Zea-Ponce, Y.; Rodenhiser-Hill, J.; Mann, J.J.; Van Heertum, R.L.; Cooper, T.B.;
Carlsson, A.; Laruelle, M. Modulation of amphetamine-induced striatal dopamine release by ketamine in
humans: Implications for schizophrenia. Biol. Psychiatry 2000, 48, 627–640. [CrossRef]
339. Javitt, D.C.; Balla, A.; Burch, S.; Suckow, R.; Xie, S.; Sershen, H. Reversal of phencyclidine-induced dopaminergic
dysregulation by N-methyl-Daspartate receptor/glycine-site agonists. Neuropsychopharmacology 2004, 29, 300–307.
[CrossRef] [PubMed]
340. Akbarian, S.; Sucher, N.J.; Bradley, D.; Tafazzoli, A.; Trinh, D.; Hetrick, W.P.; Potkin, S.G.; Sandman, C.A.;
Bunney, W.E., Jr.; Jones, E.G. Selective alterations in gene expression for NMDA receptor subunits in
prefrontal cortex of schizophrenics. J. Neurosci. 1996, 16, 19–30. [PubMed]
341. Coyle, J.T.; Tsai, G. NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia.
Int. Rev. Neurobiol. 2004, 59, 491–515. [PubMed]
342. Kornhuber, J.; Mack-Burkhardt, F.; Riederer, P.; Hebenstreit, G.F.; Reynolds, G.P.; Andrews, H.B.;
Beckmann, H. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients.
J. Neural Transm. 1989, 77, 231–236. [CrossRef] [PubMed]
343. Berk, M.; Plein, H.; Csizmadia, T. Supersensitive platelet glutamate receptors as a possible peripheral marker
in schizophrenia. Int. Clin. Psychopharmacol. 1999, 14, 119–122. [CrossRef] [PubMed]
344. Javitt, D.C.; Spencer, K.M.; Thaker, G.K.; Winterer, G.; Hajós, M. Neurophysiological biomarkers for drug
development in schizophrenia. Nat. Rev. Drug Discov. 2008, 7, 68–83. [CrossRef] [PubMed]
345. Tsai, G.; Passani, L.A.; Slusher, B.S.; Carter, R.; Baer, L.; Kleinman, J.E.; Coyle, J.T. Abnormal excitatory
neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry 1995, 52, 829–836. [CrossRef]
[PubMed]
346. Kim, J.S.; Kornhuber, H.H.; Schmid-Burgk, W.; Holzmüller, B. Low cerebrospinal fluid glutamate in
schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 1980, 20, 379–382. [CrossRef]
347. Sumiyoshi, T.; Jin, D.; Jayathilake, K.; Lee, M.; Meltzer, H.Y. Prediction of the ability of clozapine to treat
negative symptoms from plasma glycine and serine levels in schizophrenia. Int. J. Neuropsychopharmacol.
2005, 8, 451–455. [CrossRef] [PubMed]
348. Hashimoto, K.; Engberg, G.; Shimizu, E.; Nordin, C.; Lindström, L.H.; Iyo, M. Reduced D-serine to total
serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients. Prog. Neuropsychopharmacol.
Biol. Psychiatry 2005, 29, 767–769. [CrossRef] [PubMed]
349. Song, J.; Viggiano, A.; Monda, M.; De Luca, V. Peripheral glutamate levels in schizophrenia: Evidence from
a meta-analysis. Neuropsychobiology 2014, 70, 133–141. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 36 of 38
350. Uzbay, T.; Goktalay, G.; Kayir, H.; Eker, S.S.; Sarandol, A.; Oral, S.; Buyukuysal, L.; Ulusoy, G.; Kirli, S.
Increased plasma agmatine levels in patients with schizophrenia. J. Psychiatr. Res. 2013, 47, 1054–1060.
[CrossRef] [PubMed]
351. Bartha, R.; Williamson, P.C.; Drost, D.J.; Malla, A.; Carr, T.J.; Cortese, L.; Canaran, G.; Rylett, R.J.; Neufeld, R.W.
Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic
patients and healthy controls by proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 1997, 54,
959–965. [CrossRef] [PubMed]
352. Ohnuma, T.; Sakai, Y.; Maeshima, H.; Hatano, T.; Hanzawa, R.; Abe, S.; Kida, S.; Shibata, N.; Suzuki, T.;
Arai, H. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as
their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP).
Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1905–1912. [CrossRef] [PubMed]
353. Yamamori, H.; Hashimoto, R.; Fujita, Y.; Numata, S.; Yasuda, Y.; Fujimoto, M.; Ohi, K.; Umeda-Yano, S.;
Ito, A.; Ohmori, T.; et al. Changes in plasma D-serine, L-serine, and glycine levels in treatment-resistant
schizophrenia before and after clozapine treatment. Neurosci. Lett. 2014, 582, 93–98. [CrossRef] [PubMed]
354. Ohnuma, T.; Sakai, Y.; Maeshima, H.; Higa, M.; Hanzawa, R.; Kitazawa, M.; Hotta, Y.; Katsuta, N.;
Takebayashi, Y.; Shibata, N.; et al. No correlation between plasma NMDA-related glutamatergic amino acid
levels and cognitive function in medicated patients with schizophrenia. Int. J. Psychiatry Med. 2012, 44, 17–27.
[CrossRef] [PubMed]
355. Heresco-Levy, U.; Javitt, D.C.; Ebstein, R.; Vass, A.; Lichtenberg, P.; Bar, G.; Catinari, S.; Ermilov, M. D-serine
efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Biol. Psychiatry 2005, 57, 577–585. [CrossRef] [PubMed]
356. Lane, H.Y.; Chang, Y.C.; Liu, Y.C.; Chiu, C.C.; Tsai, G.E. Sarcosine or D-serine add-on treatment for acute
exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch. Gen. Psychiatry
2005, 62, 1196–1204. [CrossRef] [PubMed]
357. Tuominen, H.J.; Tiihonen, J.; Wahlbeck, K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst. Rev.
2006, 2, CD003730.
358. Chaki, S.; Hikichi, H. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
Curr. Pharm. Des. 2011, 17, 94–102. [CrossRef] [PubMed]
359. Conn, P.J.; Lindsley, C.W.; Jones, C.K. Activation of metabotropic glutamate receptors as a novel approach
for the treatment of schizophrenia. Trends Pharmacol. Sci. 2009, 30, 25–31. [CrossRef] [PubMed]
360. Patil, S.T.; Zhang, L.; Martenyi, F.; Lowe, S.L.; Jackson, K.A.; Andreev, B.V.; Avedisova, A.S.; Bardenstein, L.M.;
Gurovich, I.Y.; Morozova, M.A.; et al. Activation of mGlu2/3 receptors as a new approach to treat
schizophrenia: A randomized Phase 2 clinical trial. Nat. Med. 2007, 13, 1102–1107. [CrossRef] [PubMed]
361. Akbarian, S.; Kim, J.J.; Potkin, S.G.; Hagman, J.O.; Tafazzoli, A.; Bunney, W.E.; Jones, E.G. Gene expression
for Glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.
Arch. Gen. Psychiatry 1995, 52, 258–266. [CrossRef] [PubMed]
362. Benes, F.M.; Berretta, S. GABAergic interneurons: Implications for understanding schizophrenia and bipolar
disorder. Neuropsychopharmacology 2001, 25, 1–27. [CrossRef]
363. Benes, F.M.; Sorensen, I.; Vincent, S.L.; Bird, E.D.; Sathi, M. Increased density of glutamate-immunoreactive
vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cereb. Cortex 1992, 2,
503–512. [CrossRef] [PubMed]
364. Gonzalez-Burgos, G.; Hashimoto, T.; Lewis, D.A. Alterations of cortical GABA neurons and network
oscillations in schizophrenia. Curr. Psychiatry Rep. 2010, 12, 335–344. [CrossRef] [PubMed]
365. Guidotti, A.; Auta, J.; Davis, J.M.; Dong, E.; Grayson, D.R.; Veldic, M.; Zhang, X.; Costa, E. GABAergic
dysfunction in schizophrenia: New treatment strategies on the horizon. Psychopharmacol. Berl. 2005, 180,
191–205. [CrossRef] [PubMed]
366. Lewis, D.A.; Hashimoto, T.; Volk, D.W. Cortical inhibitory neurons and schizophrenia. Nat. Rev. Neurosci.
2005, 6, 312–324. [CrossRef] [PubMed]
367. Sequeira, P.A.; Martin, M.V.; Vawter, M.P. The first decade and beyond of transcriptional profiling in
schizophrenia. Neurobiol. Dis. 2012, 45, 23–36. [CrossRef] [PubMed]
368. Costa, E.; Chen, Y.; Dong, E.; Grayson, D.R.; Kundakovic, M.; Maloku, E.; Ruzicka, W.; Satta, R.; Veldic, M.;
Zhubi, A.; et al. GABAergic promoter hypermethylation as a model to study the neurochemistry of
schizophrenia vulnerability. Expert Rev. Neurother. 2009, 9, 87–98. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 733 37 of 38
369. Grayson, D.R.; Guidotti, A. The dynamics of DNA methylation in schizophrenia and related psychiatric
disorders. Neuropsychopharmacology 2013, 38, 138–166. [CrossRef] [PubMed]
370. Guidotti, A.; Auta, J.; Chen, Y.; Davis, J.M.; Dong, E.; Gavin, D.P.; Grayson, D.R.; Matrisciano, F.; Pinna, G.;
Satta, R.; et al. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 2011,
60, 1007–1016. [CrossRef] [PubMed]
371. Veldic, M.; Guidotti, A.; Maloku, E.; Davis, J.M.; Costa, E. In psychosis, cortical interneurons overexpress
DNA-methyltransferase I. Proc. Natl. Acad. Sci. USA 2005, 102, 2152–2157. [CrossRef] [PubMed]
372. Veldic, M.; Kadriu, B.; Maloku, E.; Agis-Balboa, R.C.; Guidotti, A.; Davis, J.M.; Costa, E. Epigenetic
mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder.
Schizophr. Res. 2007, 91, 51–61. [CrossRef] [PubMed]
373. Ruzicka, W.B.; Zhubi, A.; Veldic, M.; Grayson, D.R.; Costa, E.; Guidotti, A. Selective epigenetic alteration of
layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted
microdissection. Mol. Psychiatry 2007, 4, 385–397. [CrossRef] [PubMed]
374. Hashimoto, T.; Arion, D.; Unger, T.; Maldonado-Avilés, J.G.; Morris, H.M.; Volk, D.W.; Mirnics, K.;
Lewis, D.A. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with
schizophrenia. Mol. Psychiatry 2008, 13, 147–161. [CrossRef] [PubMed]
375. Gavin, D.P.; Akbarian, S. Epigenetic and post-transcriptional dysregulation of gene expression in
schizophrenia and related disease. Neurobiol. Dis. 2012, 46, 255–262. [CrossRef] [PubMed]
376. Zhubi, A.; Veldic, M.; Puri, N.V.; Kadriu, B.; Caruncho, H.; Loza, I.; Sershen, H.; Lajtha, A.; Smith, R.C.;
Guidotti, A.; et al. An upregulation of DNA-methyltransferase 1 and 3A expressed in telencephalic
GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr. Res.
2009, 111, 115–122. [CrossRef] [PubMed]
377. Akbarian, S.; Huang, H.S. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in
schizophrenia and related disorders. Brain Res. Rev. 2006, 52, 293–304. [CrossRef] [PubMed]
378. Dracheva, S.; Elhakem, S.L.; McGurk, S.R.; Davis, K.L.; Haroutunian, V. GAD67 and GAD65 mRNA and
protein expression in cerebrocortical regions of elderly patients with schizophrenia. J. Neurosci. Res. 2004, 76,
581–592. [CrossRef] [PubMed]
379. Guidotti, A.; Auta, J.; Davis, J.M.; Di Giorgi-Gerevini, V.; Dwivedi, Y.; Grayson, D.R.; Impagnatiello, F.;
Pandey, G.; Pesold, C.; Sharma, R.; et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67)
expression in schizophrenia and bipolar disorder: A postmortem brain study. Arch. Gen. Psychiatry 2000, 57,
1061–1069. [CrossRef] [PubMed]
380. Mirnics, K.; Middleton, F.A.; Marquez, A.; Lewis, D.A.; Levitt, P. Molecular characterization of schizophrenia
viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000, 28, 53–67. [CrossRef]
381. Straub, R.E.; Lipska, B.K.; Egan, M.F.; Goldberg, T.E.; Callicott, J.H.; Mayhew, M.B.; Vakkalanka, R.K.;
Kolachana, B.S.; Kleinman, J.E.; Weinberger, D.R. Allelic variation in GAD1 (GAD67) is associated with
schizophrenia and influences cortical function and gene expression. Mol. Psychiatry 2007, 12, 854–869.
[CrossRef] [PubMed]
382. Duncan, C.E.; Webster, M.J.; Rothmond, D.A.; Bahn, S.; Elashoff, M.; Shannon Weickert, C. Prefrontal
GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia.
J. Psychiatr. Res. 2010, 44, 673–681. [CrossRef] [PubMed]
383. Lo, W.S.; Harano, M.; Gawlik, M.; Yu, Z.; Chen, J.; Pun, F.W.; Tong, K.L.; Zhao, C.; Ng, S.K.; Tsang, S.Y.; et al.
GABRB2 association with schizophrenia: Commonalities and differences between ethnic groups and clinical
subtypes. Biol. Psychiatry 2007, 61, 653–660. [CrossRef] [PubMed]
384. Ritsner, M.; Modai, I.; Gibel, A.; Leschiner, S.; Silver, H.; Tsinovoy, G.; Weizman, A.; Gavish, M.
Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patients.
J. Psychiatr. Res. 2003, 37, 549–556. [CrossRef]
385. Ramsey, J.M.; Cooper, J.D.; Penninx, B.W.J.H.; Bahn, S. Variation in serum biomarkers with sex and female
hormonal status: Implications for clinical tests. Sci. Rep. 2016, 6, 26947. [CrossRef] [PubMed]
386. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; Text Revision
(DSM-IV TR); American Psychiatric Association: Arlington County, WV, USA, 2000. Available online:
http://www.psych.org/MainMenu/Research/DSMIV.aspx (accessed on 23 March 2017).
Int. J. Mol. Sci. 2017, 18, 733 38 of 38
387. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric
Publishing Inc.: Washington, DC, USA, 2013. Available online: https://psicovalero.files.wordpress.com/2014/06/
dsm-v-manual-diagnc3b3stico-y-estadc3adstico-de-los-trastornos-mentales.pdf (accessed on 23 March 2017).
388. Rajiv Tandon, R.; Gaebel, W.; Barch, D.M.; Bustillo, J.; Gur, R.-E.; Heckers, S.; Malaspina, D.; Owen, M.J.;
Schultz, S.; Tsuang, M.; et al. Definition and description of schizophrenia in the DSM-5. Schizophr. Res. 2013,
150, 3–10. [CrossRef] [PubMed]
389. Schwarz, E.; Guest, P.C.; Rahmoune, H.; Harris, L.W.; Wang, L.; Leweke, F.M.; Rothermundt, M.; Bogerts, B.;
Koethe, D.; Kranaster, L.; et al. Identification of a biological signature for schizophrenia in serum.
Mol. Psychiatry 2012, 17, 494–502. [CrossRef] [PubMed]
390. Pillai, A.; Buckley, P.F. Reliable biomarkers and predictors of schizophrenia and its treatment. Psychiatr. Clin.
N. Am. 2012, 35, 645–659. [CrossRef] [PubMed]
391. Fond, G.; d’Albis, M.A.; Jamain, S.; Tamouza, R.; Arango, C.; Fleischhacker, W.W.; Glenthøj, B.; Leweke, M.;
Lewis, S.; McGuire, P.; et al. The promise of biological markers for treatment response in first-episode
psychosis: A systematic review. Schizophr. Bull. 2015, 41, 559–573. [CrossRef] [PubMed]
392. Stober, G.; Ben-Shachar, D.; Cardon, M.; Falkai, P.; Fonteh, A.N.; Gawlik, M.; Glenthoj, B.Y.; Grunblatt, E.;
Jablensky, A.; Kim, Y.K.; et al. Schizophrenia: From the brain to peripheral markers. A consensus paper of
the WFSBP task force on biological markers. World J. Biol. Psychiatry 2009, 10, 127–155. [CrossRef] [PubMed]
393. Landek-Salgado, M.A.; Faust, T.E.; Sawa, A. Molecular substrates of schizophrenia: Homeostatic signaling
to connectivity. Mol. Psychiatry 2016, 21, 10–28. [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
